Introduction {#s1}
============

Integrins are dimeric transmembrane proteins complexes composed of an alpha and a beta subunit. There are 18 different alpha subunits and 8 beta subunits that combine in a limited number of combinations of which 24 are currently known in mammals ([@bib68]). Integrins are essential for regulation of numerous cellular functions including cell signaling and adhesion. Nine of the eighteen integrin alpha subunits harbor a conserved I (inserted)-domain that is crucial for binding of endogenous ligands ([@bib35]). Four of these integrin alpha subunits (α~D~, α~L~, α~M~ and α~X~) form heterodimers exclusively with the β~2~ subunit, thus forming the α~D~β~2~ (CD11d/CD18), α~L~β~2~ (CD11a/CD18, LFA-1), α~M~β~2~ (CD11b/CD18, complement receptor 3 (CR3), Mac1) and α~X~β~2~ (CD11c/CD18, CR4, p150/195) integrins, respectively ([@bib3]; [@bib46]; [@bib61]; [@bib68]; [@bib73]). The β~2~ integrins have specialized roles in immune and inflammatory responses and, like other integrins, employ a two-step mechanism of bi-directional signal transmission between the interior of cells and the extracellular milieu ([@bib2]; [@bib68]). Upon activation by various intracellular signals, the inside-out signaling is initiated through rearrangement of the integrin molecule from an inactive (bent, closed, resting, low-affinity) conformation to an active (extended, open, high-affinity) conformation. Subsequent ligand binding triggers outside-in signaling of the extended integrins through activation of Src family tyrosine kinases ([@bib34]; [@bib48]; [@bib50]; [@bib62]). Src kinases phosphorylate tyrosine residues within the so-called immunoreceptor tyrosine-based activation motif (ITAM), on the cytoplasmic face of ITAM-containing transmembrane adaptor proteins, such as DAP12 or the FcR γ-chain (FcRγ) ([@bib34]; [@bib49]; [@bib50]; [@bib62]). These serve as docking sites for the tandem phosphotyrosine-binding Src homology 2 (SH2) domains of the non-receptor spleen tyrosine kinase (Syk) ([@bib34]; [@bib49]; [@bib50]; [@bib62]). Recruitment and activation of Syk then leads to assembly of a multi-protein signaling complex that contains cytosolic Syk-binding molecules and initiates further downstream signaling, ultimately triggering various cellular responses that play a central role in the innate immune defense to infection ([@bib50]).

The β~2~ integrin complement receptor 3 (CR3) is used as receptor by the 1706 residue-long RTX ([R]{.ul}epeats in [T]{.ul}o[X]{.ul}in) adenylate cyclase toxin-hemolysin (CyaA, ACT, or AC-Hly) of *Bordetella pertussis*, which plays a crucial role in virulence and immune evasion of the whooping cough agent ([@bib27]; [@bib28]; [@bib39]; [@bib75]; [@bib77]). Upon binding to CR3, CyaA penetrates myeloid phagocytes and paralyzes their bactericidal functions by catalyzing uncontrolled conversion of cytosolic ATP to the key signaling molecule cAMP ([@bib13]; [@bib28]). The toxin also hijacks maturation and proinflammatory signaling of CR3-expressing dendritic cells and it likely subverts antigen presentation and induction of adaptive T cell immune responses to bacterial infection by intraepithelial dendritic cells of host respiratory mucosa ([@bib4]; [@bib6]; [@bib7]; [@bib21]; [@bib30]; [@bib52]; [@bib58]; [@bib66]).

Here we reveal that CyaA acts as a unique type of ligand of the I-domain-containing integrin CR3, preferentially recognizing an inactive state of the integrin through interaction at a novel binding site located outside of the I-domain. CyaA thereby avoids activation of downstream signaling of the engaged CR3 *via* the key signaling kinase Syk in human monocytes. Furthermore, we show that CyaA-catalyzed elevation of cAMP effectively blocked the iC3b opsonin-elicited activation of the CR3-Syk signaling pathway in human monocytes.

Results {#s2}
=======

CyaA binds CR3 outside of its ligand-binding I-domain {#s2-1}
-----------------------------------------------------

It was previously shown that Chinese hamster ovary (CHO) cells expressing human CR3 can be used as a suitable model for studying the interaction of CyaA with CR3 ([@bib28]). Indeed, CR3 (CD11b/CD18) expressed by CHO cells allowed the binding and cAMP-elevating (cytotoxic) activities of CyaA, while the highly homologous CR4 (CD11c/CD18) was unable to bind CyaA despite sharing the same β~2~ (CD18) subunit with CR3 ([@bib28]). Therefore, to delineate the CyaA binding site(s) on CR3, we performed swapping of the homologous alpha chain segments (CD11b and CD11c) of CR3 and CR4 ([Figure 1A](#fig1){ref-type="fig"}). First, a CHO cell line stably expressing the CD18 subunit (CHO-CD18) was established ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). This was next used for generating stable cell lines that expressed similar quantities of intact CD11b (CHO-CD11b/CD18), CD11c (CHO-CD11c/CD18), or of the chimeric CD11b-CD11c heterodimeric complexes on the cell surface ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The capacity of such cells to bind CyaA was then assessed by flow cytometry and the susceptibility to CyaA penetration and enzymatic intoxication by the delivered AC domain of the toxin was measured as intracellular accumulation of cAMP. As shown in [Figure 1B](#fig1){ref-type="fig"}, replacement of the segment containing residues 614 to 682 (segment 614-682) of CD11b by the corresponding portion of CD11c caused a sharp, about ten-fold decrease of CyaA binding to the CHO-CD11b~614-682c~/CD18 transfectants, as compared to cells expressing intact CR3 ([Figure 1B](#fig1){ref-type="fig"}). This resulted in accordingly reduced toxin penetration and cAMP accumulation in cells ([Figure 1C](#fig1){ref-type="fig"}). CyaA binding was also partially reduced on cells expressing CR3 chimeras having the residues 33 to 115 (72 ± 6%), 342 to 424 (61 ± 10%), or 686 to 1152 (89 ± 11%) of CD11b replaced by the corresponding segments of CD11c, respectively ([Figure 1B](#fig1){ref-type="fig"}). No reduction of CyaA binding was observed on cells expressing the remaining CD11b-CD11c/CD18 chimeras ([Figure 1B](#fig1){ref-type="fig"}), which all accumulated comparable levels of cAMP as the cells expressing intact CR3 ([Figure 1C](#fig1){ref-type="fig"}). Surprisingly, CyaA binding and subsequent intoxication of cells by cAMP were neither reduced by swapping of the homologous I-domain regions between CD11b and CD11c (CD11b~120-272c~ and CD11b~275-339c~), nor upon removal of the entire I-domain of CD11b (CD11b~Δ164-339~) ([Figure 1B,C](#fig1){ref-type="fig"}). This demonstrates that CyaA does not bind CR3 through the I-domain and rather recognizes the segment containing residues 614 to 682 that encompasses the C-terminal end of the last repeat of the β-propeller domain and the N-terminal portion of the thigh domain of CD11b. This finding is consistent with the sequence alignment by the Jotun Hein method (Lasergene software, DNASTAR) showing that the 614-682 segments of CD11b and CD11c are only 41% identical at the amino acid level, compared to the entire CD11b and CD11c subunits that exhibit an overall 61% sequence identity. Since, however, some other segments of CD11b appeared to be important for full toxin binding to CR3 as well, these results suggest that CyaA likely binds the integrin through a multivalent interaction, making contacts with several integrin segments. Moreover, CyaA bound CD11b only when this was associated with CD18 and not when the CD11b subunit was expressed alone on the surface of CHO-CD11b cells ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).10.7554/eLife.10766.003Figure 1.Residues 614-682 of CD11b are crucial for CyaA binding and penetration into cells.(****A****) The CD11 subunits of β~2~ integrins consist of a long N-terminal extracellular domain, a single-pass transmembrane segment (TS) and a short C-terminal cytoplasmic tail, respectively. The N-terminal part of the extracellular domain harbors seven β-sheet repeats (numbers in boxes), forming a β-propeller domain, which is followed by the thigh, calf-1 and calf-2 domains. The I-domain segment, inserted between repeats 2 and 3 of the β-propeller domain, plays a critical role in interaction of the I-domain-containing integrins with their endogenous ligands. To map the CyaA binding site on the CD11b subunit, segments of CD11b (green) were systematically replaced with their CD11c counterparts (blue). In the CD11b~Δ164-339~ molecule, the entire I domain of CD11b was deleted. (****B****) 2x10^5^ CHO cells expressing integrin molecules were incubated with 2 µg/ml of CyaA-biotin, the surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry. CyaA binding was expressed as percentage of toxin binding to CHO cells expressing the native form of CD11b/CD18. Each bar represents the mean value with SD of at least five independent experiments performed in duplicate or triplicate. Significantly reduced binding of CyaA to mutant integrins in comparison with intact CD11b/CD18 is indicated (\*\*\*\*, p\<0.0001; ANOVA). (****C****) 1x10^5^ CHO cells expressing integrin molecules were incubated with various concentrations of CyaA and the amounts of accumulated cAMP were determined in cell lysates by ELISA. Each point represents the mean value ± SD of at least seven determinations from at least three independent experiments. Significant differences between mean values of cAMP intoxication of cells expressing intact CD11b/CD18 and mutant integrins are shown (\*\*\*\*, p\<0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.003](10.7554/eLife.10766.003)10.7554/eLife.10766.004Figure 1---figure supplement 1.Expression of the CD18 subunit on the surface of CHO cells.A CHO cell line was transfected with a plasmid construct encoding CD18 and the positively transfected cells were selected using a cell sorter. The expression of the CD18 subunit (violet) on the cell surface was examined by flow cytometry upon staining of 2x10^5^ cells with the anti-CD18 mAb MEM-48. CHO cells transfected with an empty vector were processed in parallel and used as negative control (grey). A typical flow cytometry histogram from one representative binding experiment out of five performed is given. RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.004](10.7554/eLife.10766.004)10.7554/eLife.10766.005Figure 1---figure supplement 2.Binding of mAbs and CyaA to CHO cells expressing CD11b/CD18, CD11c/CD18 and the CD11b-CD11c/CD18 chimeras.A CHO cell line stably expressing intact CD18 subunit was transfected with plasmid constructs encoding CD11b, CD11c, or their respective chimeric variants. Cells stably expressing the integrin molecules were selected using a cell sorter. The expression levels of CD11b/CD18 (green), CD11c/CD18 (blue) and CD11b-CD11c/CD18 chimeras (red) on the cell surface were examined by flow cytometry upon staining of 2x10^5^ cells with the ICRF 44 mAb (recognizing the I-domain of CD11b (left panels)), the OKM1 mAb (recognizing segment 614-682 of CD11b (middle left panels)), or the 3.9 mAb (recognizing the I-domain of CD11c (middle right panels)). The cells were also analyzed for capacity to bind CyaA: 2x10^5^ transfected cells were incubated with 2 μg/ml of CyaA-biotin, the surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry (right panels). A typical histogram from one representative binding experiment out of five performed is shown for binding of the respective mAb (ICRF 44, OKM1 or 3.9), or CyaA to each integrin variant. CHO cells expressing no β~2~ integrin (transfected with empty vectors) were processed in parallel and used as negative control (grey). RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.005](10.7554/eLife.10766.005)10.7554/eLife.10766.006Figure 1---figure supplement 3.CyaA recognizes CD11b only in the heterodimeric complex with CD18.(**A** and **B**) 1x10^5^ CHO cells stably expressing intact dimeric CD11b/CD18 or its individual monomeric subunits CD11b or CD18 were stained with the anti-CD11b mAb OKM1 (****A****) or the anti-CD18 mAb MEM-48 (****B****) and analyzed by flow cytometry. A typical overlay flow cytometry histogram from one representative binding experiment out of three performed is given. (****C****) 1x10^5^ integrin-transfected CHO cells were incubated with different concentrations of Dy647-labeled CyaA and the cells were analyzed by flow cytometry. CyaA binding data were deduced from the mean fluorescence intensities of three independent experiments and each point represents the mean value ± SD. Binding of CyaA to cells expressing CD11b, CD18 or no β~2~ integrin was at all measured toxin concentrations significantly lower than toxin binding to cells expressing intact CD11b/CD18 (\*\*\*\*, p\<0.0001; ANOVA). CHO cells transfected with an empty vector and expressing no β~2~ integrin were processed in parallel and used as negative control (all panels). RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.006](10.7554/eLife.10766.006)

To exclude that the reduction of CyaA binding may have resulted from a structural alteration of the integrin chimeras, we next mapped the CyaA binding site on intact CR3 by performing competition experiments with a set of CD11b-specific monoclonal antibodies (mAbs; [Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) that do not activate CR3 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The I-domain-recognizing mAbs ICRF 44, 44 and 2LPM19c ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), the CD11c-specific mAb 3.9, the CD18-specific mAb MEM-48 and the isotype control mAbs, all failed to substantially reduce CyaA binding to CR3 ([Figure 2B](#fig2){ref-type="fig"}). In contrast, CyaA was strongly outcompeted from binding to intact CR3 by the excess of OKM1, VIM12, or M1/70 mAbs ([Figure 2B)](#fig2){ref-type="fig"} that recognize epitopes located between the residues 614 to 682 of CD11b ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This strongly supports the conclusion reached by the CD11b-CD11c domain swapping experiments that the segment encompassing residues 614 to 682 of CD11b is specifically involved in binding of CyaA. In addition, CyaA binding to CR3 was strongly inhibited by the MEM-174 mAb ([Figure 2B](#fig2){ref-type="fig"}) that recognizes the CD11b segment comprised between residues 342 to 424 ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This also concurs with the results of the segment swapping experiments, showing that the segment 342-424 along with some other segments of CD11b may also be contributing to CyaA binding to CR3.10.7554/eLife.10766.007Figure 2.Antibodies recognizing the same segments of CD11b as CyaA block its binding to CR3.(****A****) Schematic representation showing the binding segments of a set of mAbs in the CD11b subunit of CR3, which were mapped by flow cytometry. The ICRF 44, 44 and 2LPM19c mAbs recognize the I-domain of CD11b, the major ligand binding site of CR3. The MEM-174, or OKM1, VIM12 and M1/70 mAbs target amino acid segments 342-424 or 614-682 of CD11b, respectively, which are important for CyaA binding. (****B****) 2x10^5^ CHO-CD11b/CD18 cells were preincubated without or with saturating concentrations of different mAbs and then incubated with 2 µg/ml of CyaA-biotin. Surface-bound CyaA-biotin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry. CyaA binding was expressed as percentage of toxin binding to CHO-CD11b/CD18 cells treated without mAb. Each bar represents the mean value with SD of at least eight determinations from at least three independent experiments. Significant differences between mean values of CyaA binding to mAb-untreated cells and cells treated with different mAbs are indicated (\*\*\*, p\<0.001; \*\*\*\*, p\<0.0001; ANOVA). 3.9, CD11c-specific mAb; MEM-48, CD18-specific mAb; IgG1, IgG2a and IgG2b, isotype control mAbs.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.007](10.7554/eLife.10766.007)10.7554/eLife.10766.008Figure 2---figure supplement 1.Flow cytometry profiles of anti-CD11b mAbs on CHO cells expressing the integrin CD11b/CD18 and its mutant variants.2x10^5^ CHO cells stably expressing intact CD11b/CD18, or the mutant variant lacking the I-domain (CD11b~Δ164-339~/CD18), or two CR3-CR4 chimeras (CD11b~342-424c~/CD18 and CD11b~614-682c~/CD18) with a strongly reduced capacity to bind CyaA were left unstained (grey) or were stained with a panel of anti-CD11b mAbs (red). The cells were analyzed for their capacity to bind mAbs by flow cytometry and typical overlay histograms from one representative binding experiment out of five performed are shown. RFI, relative fluorescence intensity. The data confirmed that the ICRF 44, 44 and 2LPM19c mAbs recognize the I-domain of CR3 and revealed that the MEM-174 mAb has an epitope in the segment 342-424 of CD11b and the OKM1, VIM12 and M1/70 mAbs target the segment 614-682 of CD11b.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.008](10.7554/eLife.10766.008)10.7554/eLife.10766.009Figure 2---figure supplement 2.Anti-CD11b antibodies do not activate CR3.2x10^5^ CHO-CD11b/CD18 cells were preincubated without or with saturating concentrations of the indicated anti-CD11b mAbs and the CR3 was stained with the integrin activation-reporting anti-CD18 mAb MEM-148. MEM-148 binding was determined by flow cytometry and expressed as percentage of MEM-148 binding to CHO-CD11b/CD18 cells treated without mAb. Each bar represents the mean value with SD of two independent experiments performed in duplicate. Significant differences between mean values of MEM-148 binding to mAb-untreated cells and cells treated with different anti-CD11b mAbs are indicated (\*\*\*, p\<0.001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.009](10.7554/eLife.10766.009)

To confirm that the 614-682 segment of CD11b is the principal binding site of CyaA, we transferred it into the context of the CD11c subunit of CR4 ([Figure 3A](#fig3){ref-type="fig"}). Since mAbs recognizing CD11b and CD11c with equal efficacy are not available, a fluorescent YFP tag was added to the C-termini of CD11b, CD11c and CD11c~614-682b~ molecules ([Figure 3A](#fig3){ref-type="fig"}). This allowed cytometric selection of stably transfected CHO clones expressing similar quantities of the integrins on the cell surface ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As shown in [Figure 3B](#fig3){ref-type="fig"}, the CD11c~614-682b~-YFP/CD18 chimera bound different concentrations of CyaA with substantially higher efficacy (on average 24-fold higher) than the intact CD11c-YFP/CD18 complex and the chimera exhibited only a slightly lower efficacy of toxin binding (on average 1.7-fold lower) than the CD11b-YFP/CD18 integrin itself ([Figure 3B](#fig3){ref-type="fig"}). Consistently, the CHO-CD11c~614-682b~-YFP/CD18 cells were efficiently penetrated by CyaA and accumulated high levels of cAMP ([Figure 3C](#fig3){ref-type="fig"}). The segment encompassing residues 614 to 682 of CD11b, hence, constitutes an autonomous CyaA-binding structure that enables toxin penetration into cells even when located in the context of the CD11c/CD18 integrin molecule.10.7554/eLife.10766.010Figure 3.Residues 614 to 682 of CD11b confer CyaA binding to CD11c.(****A****) Schematic representation of the CD11c subunit (blue) with residues 614--682 replaced by the corresponding residues of CD11b (green). All CD11 molecules were C-terminally fused to yellow fluorescent protein (YFP) to allow quantification of expression. (****B****) 2x10^5^ CHO cells expressing integrin molecules were incubated with different concentrations of CyaA-biotin and the surface-bound toxin was labeled with streptavidin-PE. The cells were analyzed by flow cytometry and mean fluorescence intensities of CyaA binding were plotted against the concentrations of CyaA. Each point represents the mean value ± SD of two independent experiments performed in triplicate. CyaA binding to cells expressing CD11c~614-682b~-YFP/CD18, or CD11b-YFP/CD18 was at all measured CyaA concentrations significantly higher in comparison with cells expressing intact CD11c-YFP/CD18 (p\<0.0001; ANOVA). RFI, relative fluorescence intensity. (****C****) 1x10^5^ CHO cells expressing integrin molecules were incubated with various concentrations of CyaA and the amounts of accumulated cAMP were determined in cell lysates by ELISA. Each point represents the mean value ± SD of two independent experiments performed in duplicate. Significant differences between mean values of cAMP intoxication of cells expressing CD11c~614-682b~-YFP/CD18, or CD11b-YFP/CD18 and intact CD11c-YFP/CD18 are shown (\*, p\<0.05; \*\*, p\<0.01; \*\*\*\*, p\<0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.010](10.7554/eLife.10766.010)10.7554/eLife.10766.011Figure 3---figure supplement 1.Expression of integrin variants fused with a fluorescent YFP protein on the surface of CHO cells and binding of CyaA to transfected cells.A CHO cell line stably expressing the intact CD18 subunit was transfected with plasmid constructs encoding CD11b-YFP, CD11c-YFP or CD11c~614-682b~-YFP and cells stably expressing the integrin molecules were selected using a cell sorter. The expression levels of CD11b-YFP/CD18 (green), CD11c-YFP/CD18 (blue) and CD11c~614-682b~-YFP/CD18 chimera (red) on the surface of 2x10^5^ cells were examined by flow cytometry for YFP (left panels), or upon staining of cells with mAb recognizing CD11b (MEM-174, middle left panels), or CD11c (3.9, middle right panels). The cells were also analyzed for capacity to bind CyaA: 2x10^5^ transfected cells were incubated with 2 μg/ml of CyaA-biotin, the surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry (right panels). CHO cells expressing no β~2~ integrin (transfected with empty vectors) were processed in parallel and used as negative control (grey). Typical flow cytometry histograms from one representative binding experiment out of four performed are shown. RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.011](10.7554/eLife.10766.011)

CyaA recognizes its binding site on CD11b through electrostatic interaction {#s2-2}
---------------------------------------------------------------------------

To analyze the binding interaction of CyaA with CR3 in molecular detail, we employed a set of *in silico* approaches to predict the key residues involved. First, the known 3D structure of the homologous CR4 integrin ([@bib82]) was used as a template for construction of a homology model of the 3D structure of CR3. In parallel, the structure of the CR3 binding site located within residues 1166 to 1287 (segment 1166-1287) of CyaA ([@bib19]) was predicted *ab initio*, using I-TASSER ([@bib60]). Flexible side chain docking of CR3 and of the segment 1166-1287 of CyaA by the ClusPro server ([@bib12]) was next used to predict the most probable interacting residues of the two proteins ([Figure 4A,B](#fig4){ref-type="fig"}). Second, the α subunits of all four β~2~ integrins were aligned by the Jotun Hein method (Lasergene software, DNASTAR) and residues that are present at a given position only in the 614-682 segment of CD11b were considered as potentially involved in CyaA binding. Finally, the theoretical isoelectric points of the interacting segments (3.76 for 1166-1287 segment of CyaA and 8.27 for 614-682 segment of CD11b) were taken into account. The sum of these considerations suggested that the negatively charged residues of the 1166-1287 segment of CyaA might be involved in the interaction with positively charged residues within the 614-682 segment of CD11b.10.7554/eLife.10766.012Figure 4.Electrostatic interaction of oppositely charged residues underlies CyaA binding to CR3.(****A****) 3D structure of CR3 was modeled by homology onto the known 3D structure of CR4. The structure of the CD11b binding site within the segment 1166-1287 of CyaA was predicted using I-TASSER. For clarity, only the CD11b subunit is shown. (****B****) To identify interacting residues, a flexible side chain docking of the segment 1166-1287 of CyaA to CR3 was performed using the ClusPro server. (****C****) Different concentrations of Dy647-labeled intact CyaA or its variants with point mutations in the CD11b binding site of the toxin were incubated with 2x10^5 ^CHO cells expressing intact CR3 and the cells were analyzed by flow cytometry. Mean fluorescence intensities of binding of intact CyaA or its variants were plotted against the toxin concentrations. Each point represents the mean value ± SD of four independent experiments. Binding of CyaA mutant variants to cells was at all measured concentrations significantly lower than binding of intact CyaA (p\<0.0001; ANOVA). RFI, relative fluorescence intensity. (****D****) Different concentrations of intact CyaA and its mutant variants were incubated with 1x10^5 ^CHO cells expressing intact CR3 and intracellular levels of cAMP were determined by ELISA. Each point represents the mean value ± SD of two independent experiments performed in triplicate. Intoxication of cells by CyaA mutant variants was at all measured concentrations significantly lower than intoxication of cells by intact CyaA (p\<0.0001; for CyaA~E1232+D1234A~ at 20 ng/ml p\<0.001; ANOVA). (****E****) 2x10^5^ CHO cells expressing integrin molecules were incubated with 2 µg/ml of CyaA-biotin, the surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry. CyaA binding was expressed as percentage of toxin binding to CHO cells expressing the native form of CD11b/CD18. Each bar represents the mean value with SD of two independent experiments performed in duplicate. Significantly reduced binding of CyaA to mutant integrins in comparison with intact CD11b/CD18 is indicated (\*\*\*\*, p\<0.0001; ANOVA). (****F****) 1x10^5^ CHO cells expressing different integrin molecules were incubated with various concentrations of CyaA and the amounts of accumulated cAMP were determined in cell lysates by ELISA. Each point represents the mean value ± SD of six independent experiments. Intoxication of cells expressing CD11b~R662A+R664A+R666A~/CD18 or no β~2~ integrin was in concentrations ranging from 5 to 20 ng/ml of CyaA significantly lower than intoxication of cells expressing intact CD11b/CD18 (p\<0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.012](10.7554/eLife.10766.012)10.7554/eLife.10766.013Figure 4---figure supplement 1.Expression of CD11b/CD18 and of its mutant variants on the surface of CHO cells and binding of CyaA to transfected cells.A CHO cell line stably expressing the intact CD18 subunit was transfected with plasmid constructs encoding intact CD11b or its mutant variants with the charged and hydrophilic residues within the segment 614-682 replaced with alanine residues. Cells stably expressing integrin molecules were selected using a cell sorter. The expression levels of CD11b/CD18 (green) and its mutant variants (red) on the cell surface were examined by flow cytometry after staining of 2x10^5^ cells with the 2LPM19c mAb recognizing the I-domain of CD11b (left panels), or the OKM1 mAb recognizing the mutagenized segment 614-682 of CD11b (middle panels). The cells were also analyzed for capacity to bind CyaA: 2x10^5^ transfected cells were incubated with 2 μg/ml of CyaA-biotin, the surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry (right panels). CHO cells expressing no β~2~ integrin (transfected with empty vectors) were processed in parallel and used as negative control (grey). Typical flow cytometry histograms from one representative binding experiment out of four performed are shown. RFI, relative fluorescence intensity. In contrast to other substitutions in the segment 614-682 of CD11b, the triple substitution E625A+N627A+R629A abolished binding of OKM1, suggesting that the epitope recognized by OKM1, or part of it, comprises these residues.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.013](10.7554/eLife.10766.013)10.7554/eLife.10766.014Figure 4---figure supplement 2.Staining of CHO cells expressing intact CD11b/CD18 and of its two mutant variants with the four mAbs that block the binding of CyaA.2x10^5^ CHO cells stably expressing intact CD11b/CD18, or its mutant variants exhibiting significantly reduced capacity to bind CyaA, were stained with the anti-CD11b mAbs that block CyaA binding. The cells were analyzed by flow cytometry and antibody binding was expressed as percentage of mAb binding to CHO cells expressing the native form of CD11b/CD18. Each bar represents the mean value with SD of four independent experiments. Significant differences between mean values of mAb binding to cells expressing mutant integrin and cells expressing intact CD11b/CD18 are indicated (\*\*\*\*, p\< 0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.014](10.7554/eLife.10766.014)

Therefore, the predicted negatively charged glutamate and aspartate residues of the 1166-1287 segment of CyaA were substituted by alanine. As shown in [Figure 4C,D](#fig4){ref-type="fig"}, the CyaA~D1193A+D1194A+E1195A~ and CyaA~E1232+D1234A~ constructs exhibited a strongly reduced capacity to bind and penetrate CR3-expessing CHO cells. Further, combinations of alanine substitutions were also introduced in place of charged and hydrophilic residues within the 614-682 segment of CD11b and six mutant CD11b molecules were stably expressed on the surface of CHO-CD18 cells ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). No statistically significant drop of CyaA binding ([Figure 4E](#fig4){ref-type="fig"}) and cAMP elevation ([Figure 4F](#fig4){ref-type="fig"}) was observed in the cells expressing CR3 variants with the combinations of substitutions R619A+K621A, E625A+N627A+R629A, K644A+K646A, or E650A+R652A within the 614-682 segment of CD11b, respectively. In contrast, alanine substitutions of the three positively charged arginine residues at positions 662, 664 and 666 of CD11b almost completely abolished binding of CyaA to the CR3 mutant variant and a significant reduction of CyaA binding was also observed with cells expressing the CD11b~K659+T661A~/CD18 construct ([Figure 4E](#fig4){ref-type="fig"}). As shown in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, this loss or reduction of CyaA binding was not due to an alteration of the structure of the CyaA binding site within the mutant integrins, as these bound the CyaA-blocking mAbs MEM-174, OKM1 and VIM12 to the same extent as the intact CR3. The only exception was the CyaA-blocking mAb M1/70, which exhibited reduced binding to both mutant integrins, similarly as CyaA. This indicates that the M1/70 mAb and CyaA may recognize the same epitope within the 614-682 segment of CD11b. In comparison to CHO cells expressing intact CR3, CyaA produced importantly lower intracellular cAMP levels in cells expressing CD11b~R662A+R664A+R666A~/CD18 ([Figure 4F](#fig4){ref-type="fig"}). Taken together, our mutagenesis experiments confirmed the computational predictions and identified the residues involved in CD11b recognition by CyaA.

CyaA preferentially binds an inactive, low-affinity conformation of CR3 {#s2-3}
-----------------------------------------------------------------------

Since endogenous ligands preferentially bind the I-domain of activated CR3, the unique location of the CyaA binding site prompted us to test whether CyaA differentiates between the inactive (bent) and active (extended) conformation of CR3. For this experiment, a leukocyte-enriched fraction was isolated from fresh human blood and treated (or not) with phorbol 12-myristate 13-acetate (PMA) that is a known agonist activating CR3 ([@bib15]). The cells were subsequently stained with mAbs and exposed to different concentrations of CyaA, before being analyzed by flow cytometry. Monocytes were gated based on light-scatter characteristics and expression of CD14 and used for assessment of CyaA binding. As shown in [Figure 5A,B](#fig5){ref-type="fig"}, PMA-stimulated monocytes expressed the same amounts of CR3 as untreated monocytes (detected with OKM1 mAb), but bound the toxin with a significantly lower efficiency. This was clearly due to conformational rearrangement of CR3 on PMA-activated monocytes, as the activated cells bound approximately two-fold more of the activation-reporting mAb MEM-148 ([@bib16]) than the non-activated monocytes ([Figure 5A](#fig5){ref-type="fig"}). The monocytes pretreated with PMA then accumulated substantially lower intracellular levels of cAMP upon exposure to CyaA than the non-activated cells ([Figure 5C](#fig5){ref-type="fig"}). Similarly, activation of CR3 by pretreatment of cells with Mn^2+^ ions ([@bib1]; [@bib44]) reduced toxin binding and cAMP accumulation in monocytes ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.10766.015Figure 5.CyaA preferentially recognizes the inactive (bent) conformation of CR3.(**A, B**) A leukocyte-enriched fraction prepared from fresh whole blood was treated without or with 100 nM PMA to activate CR3. The cells were promptly stained with the OKM1 mAb recognizing both CR3 conformations, or with the MEM-148 mAb recognizing the extended integrin conformation (****A****), or with different concentrations of Dy647-labeled CyaA (****B****) in a combination with anti-CD14 mAb. After 2 min, cells were analyzed by flow cytometry, monocytes were gated based on light-scatter characteristics and expression of CD14 and used for calculation of mAbs and CyaA binding. Binding of mAbs, or CyaA (at the highest tested concentration) to PMA-untreated cells was taken as 100%. Each value represents the mean with SD of three independent experiments performed in duplicate using three different donors. Significant differences between mean values of mAbs or CyaA binding to cells treated with buffer alone and cells treated with PMA are shown (\*, p\<0.05; \*\*, p\< 0.01; \*\*\*, p\<0.001; Student's t-test). (****C****) 1x10^5^ human primary monocytes were pretreated without or with 100 nM PMA and incubated with indicated concentrations of CyaA. The amounts of accumulated cAMP were determined in cell lysates by ELISA. Each point represents the mean value ± SD of seven independent experiments performed in duplicate using cells of seven different donors. Significant differences between mean values of cAMP intoxication of monocytes incubated in the absence and in the presence of PMA are shown (\*, p\<0.05; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001; Student's t-test). (**D-G**) The bent and extended conformers of sCR3 were immobilized to a Bio-Rad ProteOn XPR36 GLC sensor chip and the MEM-48 mAb recognizing both conformations of sCR3 (****D****), or the MEM-148 mAb recognizing the extended integrin conformation (****E****) were used as controls. To analyze the interaction between the bent (****F****), or extended (****G****) conformation of sCR3 and the toxin, CyaA∆H was passed over the chip surface at concentrations of 20, 40, 80, 160 and 320 µg/ml. The data were analyzed by global fitting of the response curves using a bivalent analyte model and calculated kinetic parameters are given in *[Table 1](#tbl1){ref-type="table"}*.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.015](10.7554/eLife.10766.015)10.7554/eLife.10766.016Figure 5---figure supplement 1.CyaA preferentially recognizes the inactive (bent) conformation of CR3.(**A, B**) A leukocyte-enriched fraction prepared from fresh whole blood was treated without or with 1 mM Mn^2+^ ions to activate CR3. The cells were promptly stained with the OKM1 mAb recognizing both CR3 conformations, or with the MEM-148 mAb recognizing the extended integrin conformation (****A****), or with different concentrations of Dy647-labeled CyaA (****B****) in a combination with anti-CD14 mAb. After 2 min, cells were analyzed by flow cytometry, monocytes were gated based on light-scatter characteristics and expression of CD14 and used for calculation of mAbs and CyaA binding. Binding of mAbs, or CyaA (at the highest tested concentration) to Mn^2+^-untreated cells was taken as 100%. Each value represents the mean with SD of three independent experiments performed in duplicate using three different donors. Significant differences between mean values of mAbs or CyaA binding to cells treated with buffer alone and cells treated with Mn^2+^ ions are shown (\*, p\<0.05; \*\*, p\<0.01; Student´s t-test). (****C**)** 1x10^5^ primary human monocytes were pretreated without or with 1 mM Mn^2+^ to activate CR3 and then incubated with indicated concentrations of CyaA. The amounts of accumulated cAMP were determined in cell lysates by ELISA. Each point represents the mean value ± SD of four independent experiments (three performed in duplicate) using cells of four different donors. Significant differences between mean values of cAMP intoxication of monocytes incubated in the absence and in the presence of Mn^2+^ are shown (\*, p\<0.05; \*\*, p\<0.01; Student's t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.016](10.7554/eLife.10766.016)10.7554/eLife.10766.017Figure 5---figure supplement 2.Isolation and characterization of the bent and extended conformers of sCR3.(****A****) Soluble ectodomain complex of CR3 secreted from CHO transfected cells was purified from cell media by affinity chromatography and the bent and extended conformers were separated by size exclusion chromatography. An overlay of chromatograms of re-analyzed samples containing either the extended (red) or the bent (green) conformer of sCR3 is shown. (**B, C**) The efficacy of separation was confirmed by transmission electron microscopy upon application of the extended (****B****) and bent (****C****) integrin conformers on glow-discharged carbon copper grids, followed by staining with uranyl formate. Inlet figures in red frames show zoomed views of the sCR3 conformers.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.017](10.7554/eLife.10766.017)

To further analyze the impact of CR3 conformation on CyaA binding, a soluble secreted form of the CR3 ectodomain complex (sCR3) was purified from supernatants of CHO cultures by immunoaffinity chromatography on MEM-174 mAb-Sepharose beads. The bent and extended conformers of sCR3 were resolved by size exclusion chromatography ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}), their conformation was confirmed by electron microscopy ([Figure 5---figure supplement 2B,C](#fig5s2){ref-type="fig"}) and the two sCR3 conformers were immobilized onto a surface plasmon resonance (SPR) sensor chip. Coupling densities and random orientation of sCR3 on the chip was verified by passage of the control mAb MEM-48 that recognizes both integrin conformations ([Figure 5D](#fig5){ref-type="fig"}). As shown in [Figure 5E](#fig5){ref-type="fig"}, the immobilization procedure preserved the conformation of the integrin molecules, since the integrin activation-reporting mAb MEM-148 bound only the immobilized extended sCR3 and not its bent form.

Since aggregation and unspecific binding to the SPR chip surface of intact CyaA was observed at the required toxin concentrations, we used a CyaA∆H construct, which lacks the hydrophobic pore-forming domain and is soluble even at high concentrations ([@bib63]). Real-time SPR measurements of CyaA∆H interaction with the immobilized sCR3 conformers exhibited typical association and dissociation curves ([Figure 5F,G](#fig5){ref-type="fig"}). Analysis of the binding curves by a bivalent analyte model then revealed that the association rate was higher and the dissociation rate was lower for the complex of the bent sCR3 conformer with CyaA∆H (K~d~ = 2.1x10^-7^ M) than for the complex of the extended sCR3 conformer with CyaA∆H (K~d~ = 6.4x10^-7^ M) ([Table 1](#tbl1){ref-type="table"}). This demonstrates that the bent CR3 conformer bound the toxin with a higher affinity than the extended conformer, confirming the data obtained by binding experiments on PMA- or Mn^2+^-activated primary monocytes.10.7554/eLife.10766.018Table 1.Kinetic parameters of CyaA∆H binding to sCR3 calculated by a bivalent analyte model.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.018](10.7554/eLife.10766.018)Ligand^a^Analytek~a1~\
\[×10^3^ M^-1^s^-1^\]k~d1~\
\[×10^-3^ s^-1^\]k~a2~\
\[×10^-4^ RU^-1^s^-1^\]k~d2~\
\[×10^-4^ s^-1^\]Bent sCR3CyaA∆H5.8 ± 0.71.2 ± 0.21.3 ± 0.23.8 ± 0.5Extended sCR32.8 ± 0.21.8 ± 0.42.7 ± 0.35.1 ± 0.6[^1]

CyaA binding to CR3 does not initiate downstream signaling {#s2-4}
----------------------------------------------------------

Binding of endogenous ligands to the I-domain of CR3 is known to trigger activation of Syk. This initiates downstream signaling and provokes multiple cellular activation responses, including complement-mediated opsonophagocytosis of bacteria ([@bib65]). We hence examined if the I-domain-independent interaction of CyaA with CR3 activates Syk in human monocytic cells. THP-1 monocytes, which bind CyaA in a CR3-dependent and saturable manner ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), were exposed to different concentrations of CyaA over a range of incubation times. Phosphorylated Syk was next immunoprecipitated from cell lysates with anti-phosphotyrosine mAb and was detected by anti-Syk mAb in immunoblots. As a positive control, the CR3-Syk signaling pathway was activated by iC3b-opsonized zymosan particles ([@bib65]). As shown in [Figure 6A](#fig6){ref-type="fig"}, Syk phosphorylation on tyrosine residues was observed after 30 min of incubation of THP-1 cells with iC3b-opsonized zymosan. No phosphorylation of Syk was, however, detected following exposure of THP-1 cells for up to 60 min to 30 ng/ml CyaA, a concentration close to physiological toxin levels ([@bib18]). Similarly, Syk activation was not observed when THP-1 cells were incubated with the enzymatically inactive CyaA-AC^-^ toxoid ([Figure 6B](#fig6){ref-type="fig"}). Neither was Syk phosphorylation triggered by THP-1 cell exposure to concentrations of up to 3 µg/ml of active CyaA toxin ([Figure 6C](#fig6){ref-type="fig"}), or of its CyaA-AC^-^ toxoid ([Figure 6D](#fig6){ref-type="fig"}) for 15 or 30 min, respectively. Hence, in contrast to iC3b, which binds through the I-domain of CR3 and triggers activation of Syk ([@bib65]), the I-domain-independent mode of CyaA binding did not trigger any CR3 signaling through Syk pathway activation.10.7554/eLife.10766.019Figure 6.CyaA binding to CR3 does not trigger Syk activation.(**A, B**) 3x10^6^ THP-1 cells were incubated with 30 ng/ml of CyaA (****A****), or CyaA-AC^-^ (****B****) for indicated times. (**C, D**) 3x10^6^ THP-1 cells were incubated with different indicated concentrations of CyaA for 15 min (****C****), or CyaA-AC^-^ for 30 min (****D**).** (**A-D**) Treated cells were lysed and cell lysates were immunoprecipitated (IP) with anti-phosphotyrosine (anti-PY) mAb. Syk-P immunoprecipitated from whole cell lysates was detected by immunoblotting (IB) with anti-Syk mAb and normalized to total Syk detected in whole cell lysates. Cells treated with iC3b-opsonized zymosan were taken as a positive control and the cells treated with buffer, or unopsonized zymosan were taken as negative controls. Each bar represents the mean value with SD of three independent experiments. In comparison to buffer-treated cells, a significant increase of Syk activation was observed only in cells treated with iC3b-opsonized zymosan (\*\*\*\*, p\<0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.019](10.7554/eLife.10766.019)10.7554/eLife.10766.020Figure 6---figure supplement 1.CyaA binds efficiently and specifically the THP-1 cells.(****A****) 2x10^5^ THP-1 cells were treated with the anti-CD11b OKM1 mAb, or with an isotype-matched mouse IgG2b control antibody and the cells were analyzed by flow cytometry. Each bar represents the mean value ± SD of two independent experiments performed in duplicate. Significant difference between mean values of OKM1 and the control mAb binding to THP-1 cells is indicated (\*\*\*\*, P \< 0.0001; Student's t-test). (****B****) 2x10^5^ THP-1 cells were preincubated without or with 25 μg/ml of the anti-CD11b OKM1 mAb for 30 min and subsequently treated with different concentrations of CyaA-biotin. The surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry. Mean fluorescence intensities of CyaA binding were plotted against toxin concentrations. Each point represents the mean value ± SD of two independent experiments performed in duplicate. Binding of CyaA to cells preincubated with the OKM1 mAb was at all measured concentrations significantly lower than binding of CyaA to cells pre-treated with buffer alone (P \< 0.01; Student's t-test). RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.020](10.7554/eLife.10766.020)

CyaA-generated cAMP effectively blocks the CR3-Syk signaling pathway {#s2-5}
--------------------------------------------------------------------

We further investigated whether intracellular cAMP signaling produced by the cell-invading CyaA toxin would interfere with the outside-in signaling of CR3. As shown in [Figure 7A](#fig7){ref-type="fig"}, Syk was efficiently activated by iC3b-opsonized zymosan in THP-1 cells that were pre-treated with buffer, or with 300 ng/ml of the enzymatically inactive CyaA-AC^-^ toxoid. However, iC3b-coated particles failed to elicit any Syk phosphorylation in THP-1 cells that were pre-incubated with 300 ng/ml of CyaA ([Figure 7A](#fig7){ref-type="fig"}). Control experiments demonstrated that CyaA and CyaA-AC^-^ bound THP-1 cells with the same efficacy ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) and that toxin binding did not alter the level of CR3 expression on the cell surface ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Nevertheless, a partial reduction of binding of the iC3b-coated particles to THP-1 cells preincubated with CyaA was observed, as compared to cells preincubated with buffer alone or with the CyaA-AC^-^ toxoid ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). Hence, the cAMP signaling action of CyaA concurrently prevented Syk activation by CR3-bound iC3b as well as it provoked a decrease of the iC3b opsonin binding.10.7554/eLife.10766.021Figure 7.CyaA-produced cAMP blocks opsonin-induced Syk activation.(****A****) 3x10^6^ THP-1 cells were incubated with 300 ng/ml of CyaA, CyaA-AC^-^ or buffer alone for 15 min and subsequently incubated with iC3b-opsonized zymosan for 30 min to activate Syk. Cells treated with buffer followed by unopsonized zymosan were used as a control. (****B****) 3x10^6^ THP-1 cells were pre-incubated with iC3b-opsonized zymosan for 15 min to activate Syk and subsequently incubated with 300 ng/ml of CyaA, CyaA-AC^-^ or buffer alone for 30 min. Cells treated with unopsonized zymosan followed by buffer were taken as negative control. Processing of cells and detection of Syk were performed as in the legend to [Figure 6](#fig6){ref-type="fig"}. Each bar represents the mean value with SD of three independent experiments. Significant differences between mean values of Syk activation in cells treated with iC3b-opsonized zymosan in the absence or presence of CyaA or CyaA-AC^-^ are shown (\*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.021](10.7554/eLife.10766.021)10.7554/eLife.10766.022Figure 7---figure supplement 1.CyaA and its enzymatically inactive variant CyaA-AC^-^ bind THP-1 cells with the same efficacy.(****A****) 2x10^5^ THP-1 cells were treated with buffer alone, or with 300 ng/ml of CyaA or CyaA-AC^-^ and then stained with CyaA-specific mAb 3D1, followed by Cy5-labeled secondary antibody (GAM-Cy5). Cells were analyzed by flow cytometry and a typical overlay histogram from one representative binding experiment out of two independent experiments performed in duplicate is shown. (****B****) The CyaA and CyaA-AC^-^ binding data were deduced from the mean fluorescence intensities of the flow cytometry experiments and the mean values with SD were expressed as fold change with respect to control cells treated with buffer alone. The mean values of CyaA and CyaA-AC^-^ binding to THP-1 cells did not significantly differ (ns; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.022](10.7554/eLife.10766.022)10.7554/eLife.10766.023Figure 7---figure supplement 2.CyaA and CyaA-AC^-^ do not alter the level of CR3 expression on the surface of THP-1 cells.(**A, B**) 2x10^5^ THP-1 cells were treated with 300 ng/ml of CyaA (green), CyaA-AC^-^ (red) or buffer (blue) for 15 min at 37°C, followed by staining with anti-CD11b mAbs ICRF 44 (****A****) or OKM1 (****B****). The cells were analyzed by flow cytometry and a typical overlay histogram from one representative binding experiment out of three independent experiments performed is shown for each mAb. THP-1 cells treated with buffer alone are shown as negative control (grey). RFI, relative fluorescence intensity. (**C, D**) The mAbs binding data were deduced from the mean fluorescence intensities of the flow cytometry experiments and the mean values with SD were expressed as fold change with respect to control unstained cells. The mean values of ICRF 44 (****C****) or OKM1 (****D****) mAb binding to THP-1 cells treated with CyaA or CyaA-AC^-^ did not significantly differ (ns; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.023](10.7554/eLife.10766.023)10.7554/eLife.10766.024Figure 7---figure supplement 3.CyaA reduces binding of iC3b-zymosan to THP-1 monocytes.(****A****) 2x10^5^ THP-1 cells were treated with 300 ng/ml of CyaA (green), CyaA-AC^-^ (red) or buffer (blue) for 15 min at 37°C, followed by iC3b-zymosan for 30 min at 37°C. Cells were analyzed by flow cytometry and a typical overlay histogram from one representative binding experiment out of two independent experiments performed in duplicate is shown. Cells treated with buffer alone are shown in grey. (****B****) The iC3b-zymosan binding data were deduced from the mean fluorescence intensities of the flow cytometry experiments and the mean values with SD were expressed as percentage of iC3b-zymosan binding to cells in the absence of CyaA or CyaA-AC^-^. Significant differences between mean values of iC3b-zymosan binding to buffer-treated cells and cells treated with CyaA or CyaA-AC^-^ are indicated (\*\*\*\*, p\<0.0001; ns, not significant; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.024](10.7554/eLife.10766.024)10.7554/eLife.10766.025Figure 7---figure supplement 4.Preincubation of THP-1 monocytes with iC3b-opsonized zymosan does not reduce binding of CyaA or of CyaA-AC^-^ to cells.(**A, B**) 2x10^5^ THP-1 cells were preincubated with buffer alone or iC3b-opsonized zymosan for 30 min at 37°C and subsequently treated with biotinylated CyaA (****A****) or CyaA-AC^-^ (****B****) for 10 min at 37°C. The surface-bound toxin was labeled with streptavidin-PE and the cells were analyzed by flow cytometry. A typical overlay histogram from one representative binding experiment out of three independent experiments performed is shown. RFI, relative fluorescence intensity. (**C-D**) The CyaA and CyaA-AC^-^ binding data were deduced from the mean fluorescence intensities of the flow cytometry experiments and the mean values with SD were expressed as fold change with respect to cells treated with buffer alone. Preincubation of THP-1 monocytes with iC3b-opsonized zymosan did not significantly change binding of CyaA (****C****) or CyaA-AC^-^ (****D****) to cells (ns; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.025](10.7554/eLife.10766.025)10.7554/eLife.10766.026Figure 7---figure supplement 5.CyaA and its enzymatically inactive variant CyaA-AC^-^ do not alter viability of THP-1 cells over the duration of the signaling experiments.(****A****) THP-1 cells were treated with buffer alone or with 300 ng/ml of CyaA or CyaA-AC^-^ for 45 min at 37°C (i.e. at the same conditions as during the signaling experiments). After washing, cells were stained with FITC-labeled Annexin V for 20 min at 20°C and analyzed by flow cytometry in the presence of 1 µg/ml of propidium iodide (PI). A typical flow cytometry dot plot from one representative binding experiment out of two independent experiments performed in triplicate is given for each sample. Cell death/apoptosis was evaluated by quadrant gating: Q1, necrotic cells; Q2, late apoptotic cells; Q3, early apoptotic cells; Q4, live cells. (****B****) The percentages of cells were calculated for each quadrant from the flow cytometry experiments and the mean values with SD were plotted as a bar chart. The mean percentages of live cells treated with CyaA or CyaA-AC^-^ did not significantly differ from buffer-treated cells (ns; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.026](10.7554/eLife.10766.026)10.7554/eLife.10766.027Figure 7---figure supplement 6.CyaA-produced cAMP blocks opsonin-induced Syk activation.(****A****) 3x10^6^ primary human monocytes were incubated with 300 ng/ml of CyaA, CyaA-AC^-^ or buffer alone for 15 min and were subsequently incubated with iC3b-opsonized zymosan for 30 min to activate Syk. Cells treated with buffer followed by unopsonized zymosan were used as a control. (****B****) 3x10^6^ primary human monocytes were pre-incubated with iC3b-opsonized zymosan for 15 min to activate Syk and subsequently incubated with 300 ng/ml of CyaA, CyaA-AC^-^ or buffer alone for 30 min. Cells treated with unopsonized zymosan followed by buffer were taken as negative control. Processing of cells and detection of Syk were performed as in the legend to [Figure 6](#fig6){ref-type="fig"}. Each bar represents the mean value with SD of three independent experiments. Significant differences between mean values of Syk activation in cells treated with iC3b-opsonized zymosan in the absence or presence of CyaA or CyaA-AC^-^ are shown (\*\*, p\<0.01; \*\*\*, p\<0.001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.027](10.7554/eLife.10766.027)

Importantly, when Syk was pre-activated by incubation of THP-1 cells with iC3b-opsonized zymosan, the subsequent addition of CyaA, but not of CyaA-AC^-^, provoked a significant drop of tyrosine phosphorylation of Syk ([Figure 7B](#fig7){ref-type="fig"}). Control experiments showed that preincubation of THP-1 cells with iC3b-opsonized zymosan did not reduce binding of CyaA or CyaA-AC^-^, respectively ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}). Moreover, the impairment of Syk phosphorylation upon CyaA treatment was not due to decreased cell viability ([Figure 7---figure supplement 5](#fig7s5){ref-type="fig"}). It can, hence, be concluded that Syk inactivation was due to signaling of the cAMP produced in cells by the penetrating CyaA toxin. Similar results were obtained when the same experiments were performed with primary human monocytes isolated from leukopacks of healthy donors ([Figure 7---figure supplement 6](#fig7s6){ref-type="fig"}). Taken together, our data show that the cAMP signaling of CyaA decreases the capacity of CR3 to bind the iC3b opsonin, prevents activation of Syk by iC3b-engaged CR3 and inactivates also Syk that has already been activated by iC3b/CR3.

Discussion {#s3}
==========

We show here that CyaA hijacks the complement receptor 3 of phagocytes by subversively binding to its bent, inactive conformation by binding to a unique site located outside of the I-domain. This novel type of CR3 interaction then enables rapid toxin penetration into phagocytic cells and elevation of cytosolic cAMP concentration, thus ablating the pro-phagocytic signaling of CR3 via Syk ([Figure 8](#fig8){ref-type="fig"}). This unprecedented mode of binding and action differentiates CyaA from all other known ligands of the I-domain-containing integrins.10.7554/eLife.10766.028Figure 8.CyaA acts as a unique ligand of the I-domain-containing integrin CR3.CyaA secreted by *B. pertussis* binds CR3 outside of its I-domain, using a unique site that encompasses the C-terminal end of the last repeat of the β-propeller domain and the N-terminal portion of the thigh domain of CD11b. CyaA preferentially binds the integrin in a non-activated (bent, low-affinity) conformation and engagement of CR3 by CyaA does not trigger Syk activation in monocytes. Moreover, CyaA-catalyzed elevation of cAMP effectively blocks the iC3b opsonin-elicited activation of CR3-Syk signaling in monocytes. It remains to be elucidated how CyaA-produced cAMP signaling suppresses Syk activity. Binding outside of the I-domain in an activation-independent mode thus enables the toxin to hijack CR3 and block its signaling, thereby enabling *B. pertussis* to evade CR3-mediated phagocytosis.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.028](10.7554/eLife.10766.028)

While the I-domain is essential for binding of ligands to I-domain-containing integrins, the CyaA toxin binds CR3 independently of the presence of the I-domain. This possibility has already been suggested by Guermonprez and co-workers, who observed that in contrast to I-domain-dependent CD11b ligands, CyaA binding does not require the presence of Mg^2+^ ions ([@bib28]). Indeed, we show that CyaA primarily recognizes the CD11b segment consisting of residues 614 to 682. This encompasses the C-terminal end of the last β-propeller repeat and the N-terminal portion of the thigh domain.

Besides interacting with the I-domain, certain ligands appear to interact to some extent also with the β-propeller domain of alpha subunits of β~2~ integrins ([@bib43]; [@bib83]). The β-propeller domain consist of seven β-sheet repeats ([Figure 1A](#fig1){ref-type="fig"}) that are arranged in a torus, or propeller, with each β-sheet representing one blade of the propeller ([@bib55]; [@bib67]; [@bib82]). Its fold is most closely related to the β subunit of the trimeric G-protein ([@bib67]) and proper folding of the β-propeller requires association of the α subunit with the β~2~ subunit ([@bib31]; [@bib45]). The β-propeller is followed by the thigh domain, exhibiting a C2-set immunoglobulin fold ([@bib11]), and by a genu region ([@bib81]; [@bib82]). The structural rearrangement at the thigh/genu interface is involved in the activation-dependent extension of the integrin α subunit ([@bib81]). It was previously suggested that the β-propeller/thigh region segment of CD11b (residues 599 to 679), comprising the principal CyaA binding site, can fold also in the absence of the CD18 subunit, since it was recognized by the OKM1 mAb when the CD11b subunit was expressed alone on COS cells ([@bib45]). Indeed, we observed here that OKM1 recognized CD11b that was expressed alone on CHO-CD11b cells ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). However, CyaA failed to bind any significantly to cells expressing the isolated CD11b subunit on their surface ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). In contrast to the OKM1 epitope, hence, the CyaA-binding site within the segment 614-682 of CD11b may acquire the correct structure (fold) only when the CD11b subunit is in complex with CD18. Alternatively, an interaction of CyaA with the CD18 subunit may also be involved in CyaA binding to CR3, even though CD18 alone was unable to bind CyaA on its own ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}).

In addition, recognition of additional segments of CD11b appears to contribute to the full capacity of CR3 to bind CyaA. Engagement of these segments likely facilitates or stabilizes the higher-affinity interaction of CyaA with the principal binding site (residues 614 to 682). Toxin interactions at several sites on CD11b would then synergize in bringing about the highly selective interaction of CyaA with the CD11b subunit of CR3. Indeed, we have previously described that an initial low-affinity interaction of CyaA with N-linked glycan chains of the C-terminal part of the CD11b subunit is a critical prerequisite for toxin binding to CR3 ([@bib29]; [@bib51]). A low-affinity interaction with abundant N-linked glycans on the integrin molecule most likely serves as the initial step of toxin pre-concentration from solution into the two-dimensional space of the cell surface. This increase of local CyaA concentration would then increase the probability of proper positioning of the toxin molecule for its subsequent high affinity interaction with specific amino acid residues of the CR3 glycoprotein. This two-step mode of CyaA-CR3 interaction is supported by the SPR binding curves which fit well using the bivalent analyte model, describing a two-step association process. Compared to a mechanism of direct single step binding from solution, a sequential binding mechanism would, indeed, lower the affinity constraints on interaction of CyaA with the ectodomain of CR3. The stability of the CyaA-CR3 complex may then be further increased by an irreversible insertion of the hydrophobic domain and of the acyl chains of CyaA into the cellular membrane, which most likely accounts for the observed high apparent affinity of toxin binding to CR3-expressing cells ([@bib28]).

It was recently proposed that CyaA can specifically bind yet another β~2~ integrin on leukocytes, the LFA-1 (CD11a/CD18) complex ([@bib56]). However, this is at odds with the initial observation of Guermonprez and co-workers that CyaA does selectively and with high affinity bind the dendritic cells and macrophages expressing CD11b/CD18, whereas B and T cell lines expressing exclusively the LFA-1 complex were recognized with substantially lower efficacy, if at all ([@bib28]). To rule out that this difference in CyaA binding was due to unequal expression levels of the integrins on various cell types, we added a fluorescent YFP tag to the C-terminus of the CD11a subunit and generated a cell line (CHO-CD11a-YFP/CD18) expressing the same quantities of the integrin molecules on the cell surface as found on the CR3-expressing cell line (CHO-CD11b-YFP/CD18) ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). As shown in [Figure 9A](#fig9){ref-type="fig"}, over a range of CyaA concentrations, the CHO-CD11a-YFP/CD18 cells bound about two orders of magnitude less CyaA toxin than the CD11b-YFP/CD18-expressing cells. Moreover, the difference in binding of CyaA to CD11a-YFP/CD18-expressing cells, CD11c-YFP/CD18-expressing cells, or the mock-transfected cells expressing no β~2~ integrin at all, was not statistically significant ([Figure 9A](#fig9){ref-type="fig"}). To exclude the concern that the residual binding of CyaA to CD11a-YFP/CD18 could be due to the presence of the YFP tag, we generated a cell line expressing comparable amounts of intact CD11a/CD18 ([Figure 9---figure supplement 2A](#fig9s2){ref-type="fig"}) and demonstrated that CyaA binds these cells as poorly as cells expressing CD11a-YFP/CD18 with the YFP tag ([Figure 9---figure supplement 2B](#fig9s2){ref-type="fig"}). In addition, we purified the intact LFA-1 integrin from human peripheral blood mononuclear cells by immunoaffinity chromatography on MEM-25 mAb-Sepharose beads and immobilized it onto an SPR sensor chip. Real-time SPR measurements revealed no CyaA∆H binding to the intact LFA-1 ([Figure 9---figure supplement 3](#fig9s3){ref-type="fig"}; cf. CyaA∆H binding to CR3 in [Figure 5F,G](#fig5){ref-type="fig"}). Finally, cells expressing CD11a-YFP/CD18 were intoxicated by CyaA to equally low cAMP levels as the control cells expressing CD11c-YFP/CD18, or lacking any β~2~ integrin, while cAMP intoxication of cells expressing CD11b-YFP/CD18 was over two orders of magnitude higher than that of the control cells ([Figure 9B](#fig9){ref-type="fig"}). All these data clearly demonstrate that CyaA binds and intoxicates cells expressing LFA-1 with equally low efficacy as cells expressing CR4, or lacking any β~2~ integrin at all.10.7554/eLife.10766.029Figure 9.CyaA binds and intoxicates cells expressing LFA-1 with equally low efficacy as cells expressing CR4, or lacking any β~2~ integrin at all.(****A****) 2x10^5^ stably transfected CHO cells expressing CD11a-YFP/CD18, CD11b-YFP/CD18, CD11c-YFP/CD18, or no β~2~ integrin were incubated with different concentrations of Dy647-labeled intact CyaA and analyzed by flow cytometry. Mean fluorescence intensities of CyaA binding were plotted against the concentrations of CyaA. RFI, relative fluorescence intensity. (****B****) 1x10^5^ CHO cells expressing integrin molecules were incubated at indicated concentrations of CyaA and the amounts of accumulated cAMP were determined in cell lysates by ELISA. (**A** and **B**) Each point represents the mean value ± SD of three independent experiments performed in duplicate. CyaA binding to or cAMP intoxication of cells expressing CD11a-YFP/CD18, CD11c-YFP/CD18, or no β~2~ integrin was at all toxin concentrations significantly lower than toxin binding to or cAMP intoxication of cells expressing intact CD11b-YFP/CD18 (p\<0.0001; ANOVA). However, CyaA binding to or cAMP intoxication of cells expressing CD11a-YFP/CD18 was at all measured toxin concentrations found to be statistically the same as toxin binding to or cAMP intoxication of cells expressing CD11c-YFP/CD18 or no β~2~ integrin at all (P \> 0.1; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.029](10.7554/eLife.10766.029)10.7554/eLife.10766.030Figure 9---figure supplement 1.Expression of integrin variants fused with a fluorescent YFP protein on the surface of CHO cells.A CHO cell line stably expressing the intact CD18 subunit was transfected with plasmid constructs encoding CD11b-YFP or CD11a-YFP and cells stably expressing the integrin molecules were selected using a cell sorter. The expression levels of CD11b-YFP/CD18 (green) and CD11a-YFP/CD18 (violet) on the surface of 2x10^5^ cells were examined by flow cytometry for YFP (left panels), or upon staining of cells with a mAb recognizing CD11b (M1/70, middle panels), or a mAb recognizing CD11a (MEM-25, right panels). CHO cells expressing no β~2~ integrin (transfected with empty vectors) were used as negative control (grey). Typical flow cytometry histograms from one representative binding experiment out of four performed are shown. RFI, relative fluorescence intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.030](10.7554/eLife.10766.030)10.7554/eLife.10766.031Figure 9---figure supplement 2.Residual binding of CyaA to CD11a-YFP/CD18 is not due to the presence of the YFP tag.(****A****) A CHO cell line stably expressing the intact CD18 subunit was transfected with a plasmid construct encoding CD11a and cells stably expressing CD11a/CD18 were selected using a cell sorter. The expression levels of CD11a/CD18 (red) on the surface of 2x10^5^ cells were examined by flow cytometry upon staining of cells with the anti-CD11a mAb MEM-25 (left panels) and compared with expression levels of CD11a-YFP/CD18 (violet). Both CD11a/CD18- and CD11a-YFP/CD18-epressing cells were also examined by flow cytometry for YFP (right panels). CHO cells expressing no β~2~ integrin (transfected with empty vectors) were used as negative control (grey). Typical flow cytometry histograms from one representative binding experiment out of four performed are shown. RFI, relative fluorescence intensity. (****B****) 2x10^5^ stably transfected CHO cells expressing CD11a/CD18, CD11a-YFP/CD18, CD11b/CD18, or no β~2~ integrin were incubated with different concentrations of Dy647-labeled intact CyaA and analyzed by flow cytometry. Mean fluorescence intensities of CyaA binding were plotted against the concentrations of CyaA. RFI, relative fluorescence intensity. Each point represents the mean value ± SD of two independent experiments performed in duplicate. CyaA binding to cells expressing CD11a/CD18, CD11a-YFP/CD18 or no β~2~ integrin was at all toxin concentrations significantly lower than toxin binding to cells expressing intact CD11b/CD18 (p\<0.0001; ANOVA). In contrast, CyaA binding to cells expressing CD11a/CD18 at all measured toxin concentrations was found to be statistically the same as toxin binding to cells expressing CD11a-YFP/CD18 or no β~2~ integrin at all (P \> 0.1; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.10766.031](10.7554/eLife.10766.031)10.7554/eLife.10766.032Figure 9---figure supplement 3.CyaA does not interact with the intact native LFA-1 integrin.(****A****) LFA-1 was purified from human peripheral blood mononuclear cells by immunoaffinity chromatography and immobilized onto an SPR sensor chip. To analyze the interaction between LFA-1 and the toxin, CyaA∆H was passed over the chip surface at concentrations of 20, 40, 80, 160 and 320 µg/ml. (****B****) The MEM-48 mAb recognizing the CD18 subunit of LFA-1 was used as positive control.**DOI:** [http://dx.doi.org/10.7554/eLife.10766.032](10.7554/eLife.10766.032)

Our findings have numerous implications for understanding of the potent immunosubversive action of CyaA on phagocytes and of its central role in *B. pertussis* virulence and escape from innate immunity control. Despite the fact that CyaA was repeatedly reported to subvert FcR- and CR3-mediated opsonophagocytosis ([@bib13]; [@bib36]; [@bib42]), little attention has been paid to the effector molecules and pathways targeted by CyaA-generated cAMP signaling. The Syk tyrosine kinase pathway, pinpointed here as the target of CyaA action, plays a central role in both FcR- and CR3-mediated phagocytosis, as it is activated immediately upon binding of immunoglobulin or iC3b opsonins to the respective FcR and CR3 receptors ([@bib14]; [@bib40]; [@bib65]). We show that CyaA bypasses the Syk-activating interaction with CR3 through a subversive preferential recognition of its bent, resting conformation and by engaging the CR3 structures outside of the I-domain of CD11b. In contrast to iC3b opsonin, binding of CyaA, or of its non-enzymatic CyaA-AC^-^ toxoid, did not trigger any CR3-mediated activation of Syk. Strikingly, CyaA-catalyzed elevation of cAMP in phagocytes effectively blocked subsequent activation of Syk through iC3b binding to CR3. Most importantly, when Syk was pre-activated by incubation of phagocytes with iC3b, the subsequent CR3-dependent invasion of CyaA into cells enabled cAMP signaling-mediated inactivation of Syk ([Figure 8](#fig8){ref-type="fig"}).

It remains to be elucidated how CyaA-produced cAMP signaling suppresses Syk activity. Two plausible working hypotheses are, nevertheless, worth mentioning in this context. The first would be based on the observation that increased cAMP levels activate the inhibitory C-terminal Src kinase (Csk) via the cAMP-dependent protein kinase PKA ([@bib74]). Csk may then directly inactivate the Src kinases by phosphorylation ([@bib74]). Inactive Src kinases would then be unable to accomplish the double phosphorylation of the ITAM-containing adaptor, which is a prerequisite for recruitment and activation of Syk ([@bib34]; [@bib48]; [@bib49]; [@bib50]; [@bib62]). A second plausible mechanism would be based on our recent observation that CyaA/cAMP-mediated signaling triggers activation of the ubiquitously expressed SH2-containing non-receptor protein tyrosine phosphatase SHP-1 (PTPN6) ([@bib9]). This phosphatase has been previously implicated in regulation of tyrosine phosphorylation of Syk and in blocking of FcγR--mediated phagocytosis ([@bib32]; [@bib37]). Experiments aimed at deciphering the mechanism by which cAMP signaling inactivates Syk are ongoing.

CR3-mediated phagocytosis involves active RhoA GTP-ase, which acts downstream of Syk ([@bib8]). We have previously shown that cAMP signaling of CyaA rapidly decreases RhoA activity and induces dephosphorylation of the actin filament-severing protein cofilin ([@bib36]). CyaA thereby provokes massive actin cytoskeleton rearrangements and unproductive membrane ruffling of macrophage cells ([@bib36]). We therefore speculate that this inhibitory intervention of the toxin at the two different signaling levels of Syk and RhoA, respectively, synergizes in bringing about a complete and rapid inhibition of CR3-mediated phagocytosis and complement-mediated opsonophagocytic killing of bacteria. CyaA would thereby subvert the central mechanism of innate defense against *B. pertussis* in naive hosts devoid of pathogen-specific antibodies, thus promoting bacterial colonization and virulence.

Besides FcR and CR3-mediated phagocytosis, Syk activity regulates a number of additional processes involved in the control of bacterial infections by the immune system. These include innate immunity mechanisms such as phagocyte chemotaxis, generation of reactive oxygen intermediates, neutrophil extracellular trap formation and degranulation of phagocytes ([@bib22]; [@bib26]; [@bib48]; [@bib72]; [@bib78]). Moreover, Syk and its homologue, the ζ-chain-associated protein kinase of 70 kDa (ZAP-70), also play a crucial role in B- and T-cell receptor signaling during induction of adaptive immune responses ([@bib70]). Indeed, chemotactic activity and oxidative burst of phagocytes, as well as the Th1/Th2 adaptive immune response balance, were both previously shown to be sensitive to the cAMP-elevating activity of CyaA ([@bib13]; [@bib24]; [@bib57]; [@bib59]; [@bib76]). This suggests that disruption of Syk/ZAP70 signaling by CyaA impairs a broad range of processes that play a crucial role in host defense against infection.

Our demonstration of targeting and efficient blocking of Syk activation by CyaA-produced cAMP thus provides a novel mechanistic insight into the prominent role played by CyaA in mediating immune evasion of *Bordetella* species pathogenic to mammals. This underpins the crucial role played by the CyaA toxin in the early stages of host colonization by *B. pertussis* ([@bib27]; [@bib39]). It further indicates that vaccine-induced neutralizing antibody response against CyaA is likely to be importantly contributing to protection against infection and colonization by *B. pertussis*. Absence of the CyaA antigen from current acellular pertussis (aP) vaccines is thus of concern ([@bib64]). It may represent one of the factors contributing to recent resurgence of pertussis in the most developed countries that use the aP vaccine ([@bib10]; [@bib47]; [@bib53]; [@bib69]; [@bib79]; [@bib80]).

Materials and methods {#s4}
=====================

Antibodies {#s4-1}
----------

Monoclonal antibodies (mAbs) 2LPM19c (mouse IgG1) and 44 (mouse IgG1), specific for human CD11b, were obtained from Santa Cruz Biotechnology, Santa Cruz, CA. MAb M1/70 (rat IgG2b) specific for murine and human CD11b was purchased from BD Pharmingen. MAb ICRF44 (mouse IgG1) specific for human CD11b was obtained from BioLegend, San Diego, CA. MAb VIM12 (mouse IgG1) specific for human CD11b was obtained from Caltag Laboratories, Burlingame, CA. MAb 3.9 (mouse IgG1) specific for human CD11c was obtained from Ancell Corporation, Bayport, MN. MAbs specific for human CD11b (MEM-174, mouse IgG2a) and CD18 (MEM-48, mouse IgG1) were a kind gift of V. Horejsi (Czech Academy of Sciences, Prague, Czech Republic). MAb OKM1 (mouse IgG2b) specific for human CD11b was purified from the OKM1 hybridoma obtained from the European Collection of Cell Cultures, Porton Down, UK. Anti-human CD11a (MEM-25, mouse IgG1), anti-human CD18 (MEM-148, mouse IgG1), anti-phosphotyrosine (P-Tyr-01, mouse IgG1) and anti-Syk (SYK-01, mouse IgG1) mAbs were purchased from Exbio, Vestec, Czech Republic. Anti-human CD14 (TÜK4, mouse IgG2a) mAb was obtained from Dako, Glostrup, Denmark. Mouse mAb 3D1 recognizing CyaA was a kind gift of E. Hewlett (University of Virginia, Charlottesville, VA). Monoclonal antibodies were unlabeled and/or conjugated with Alexa Fluor 488 (AF488), fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophycocyanin (APC) or biotin, respectively. Cy5-conjugated goat anti-mouse IgG F(ab′)~2~ fragment (GAM-Cy5) was obtained from Jackson ImmunoResearch Laboratories, West Grove, PA. Horseradish peroxidase labeled anti-mouse IgG antibody was purchased from GE Healthcare, Piscataway, NJ.

Cells and growth conditions {#s4-2}
---------------------------

CHO-K1 Chinese hamster ovary cells (ATCC CCL-61) and THP-1 human monocytic cells (ATCC TIB-202) were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and tested for the absence of mycoplasma contamination by Hoechst stain. CHO cells were grown in F12K medium (GIBCO Invitrogen, Grand Island, NY) supplemented with 10% fetal calf serum (FCS) (GIBCO Invitrogen, Grand Island, NY) and antibiotic antimycotic solution (ATB, 0.1 mg/ml streptomycin, 1000 U/ml penicillin and 0.25 µg/ml amphotericin; Sigma-Aldrich, St. Louis, MO). THP-1 cells were cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal calf serum and antibiotic antimycotic solution.

Ethics statement {#s4-3}
----------------

Commercial anonymous human blood and leukopacks were purchased from the Blood Bank of Thomayer Hospital, Prague, Czech Republic, and informed consent was therefore not applicable. Handling of cells of human origin was performed in compliance with the quality and safety requirements of the Act No. 296/2008 Coll. and the decree No. 422/2008 Coll., and the used protocols were in accordance with internal guidelines of the Institute of Microbiology of the CAS, v. v. i.

Plasmid constructs {#s4-4}
------------------

pT7CACT1 was used for co-expression of *cyaC* and *cyaA* genes in production of recombinant CyaC-activated CyaA in *Escherichia coli* under the control of the isopropyl-β-D-thiogalactopyranoside-inducible *lacZ *promoter ([@bib54]). Oligonucleotide-directed PCR mutagenesis was used to construct pT7CACT1-derived plasmids for expression of CyaA mutant variants (CyaA-D1193A+D1194A+E1195A and CyaA-E1232+D1234A, respectively) harboring negatively charged aspartate and glutamate residues of the CD11b binding site of the toxin substituted with alanine residues.

CyaA-AC^-^ toxoid, unable to convert ATP to cAMP, was expressed from pT7CACT1-derived plasmid generated by placing a synthetic BamHI linker (5'-GGATCC-3'), encoding a dipeptide GlyPhe, into the EcoRV site between codons 188 and 189 of *cyaA*, as described previously ([@bib54]). pACT∆385-828 was used to produce a deletion mutant of CyaA, CyaA∆H, lacking the hydrophobic segment between residues 385-828 ([@bib63]).

Human cDNAs encoding CD11b and CD18 were a kind gift of D. Golenbock, Boston University School of Medicine, Boston, MA ([@bib33]). Human cDNAs encoding CD11a and CD11c were purchased from Geneservice, Cambridge, UK. The cDNAs for CD11a, CD11b and CD11c were cloned into the pcDNA3 expression vector (Invitrogen, Carlsbad, CA) and the cDNA for CD18 into the pcDNA3.1/Zeo (+) expression vector (Invitrogen, Carlsbad, CA) under the control of the human cytomegalovirus immediate-early promoter.

For production of chimeric CD11b-CD11c molecules, silent mutations not altering the sequence of encoded proteins were introduced by oligonucleotide-directed PCR mutagenesis to generate restriction sites in homologous regions of the cDNAs for CD11b and CD11c. These restriction sites were then used to construct the chimeric CD11b molecules having different segments replaced by the corresponding portions of CD11c ([Figure 1A](#fig1){ref-type="fig"}), or to obtain the CD11b molecule with deleted I-domain ([Figure 1A](#fig1){ref-type="fig"}), or to construct a CD11c molecule harboring the 614-682 segment replaced by the CD11b counterpart segment ([Figure 3A](#fig3){ref-type="fig"}). All cDNAs for expression of CD11-derived proteins were constructed in the pcDNA3 vector.

To express CD11-derived proteins C-terminally fused to yellow fluorescent protein (YFP), a DNA fragment encoding YFP, originating from the plasmid pEYFP-C3 (Clontech, Ozyme, Paris, France), was fused in frame to the 3'-end of cDNAs (cloned in pcDNA3) encoding CD11a, CD11b, CD11c and CD11c~614-682b~, respectively, using standard PCR and molecular cloning techniques.

Oligonucleotide-directed PCR mutagenesis was used to construct pcDNA3-CD11b-derived plasmids for expression of the CD11b mutant variants CD11b~R619A+K621A~, CD11b~E625A+N627A+R629A~, CD11b~K644A+K646A~, CD11b~E650A+R652A~, CD11b~K659+T661A~ and CD11b~R662A+R664A+R666A~, respectively.

To express the secreted ectodomain of the integrin CR3 (sCR3), the segments encoding transmembrane helices and the C-terminal cytoplasmic tails of CD11b (codons 1106 to 1152) and of CD18 (codons 700 to 769) were replaced by short DNA segments encoding a C-terminal 6 x His tag.

Production, purification and labeling of CyaA {#s4-5}
---------------------------------------------

CyaA and its mutant variants were produced in the presence of the activating protein CyaC, using the *E. coli* strain XL1-Blue (Stratagene, La Jolla, CA) and the proteins were purified by a combination of ion exchange chromatography on DEAE-Sepharose and hydrophobic chromatography on Phenyl-Sepharose ([@bib54]). Endotoxin was removed by repeated washes of the toxin-bound resin with 60% isopropanol ([@bib23]). The preparations used in signaling experiments thus contained less than 0.1 EU/1 µg of CyaA as determined by Limulus Amebocyte Lysate assay (QCL-1000, Lonza, Walkersville, MD).

On-column labeling of CyaA and its mutant variants was performed after the DEAE-Sepharose purification step. Protein samples were diluted 4-times in ice-cold 50 mM Tris-HCl, pH 8.0 containing 1 M NaCl and loaded on Phenyl-Sepharose beads. To label CyaA with biotin, the column was extensively washed with PBS (12 mM Na~2~HPO~4~, 2 mM KH~2~PO~4~, pH 7.4, 3 mM KCl and 132 mM NaCl) and the beads were resuspended in PBS containing NHS-Sulfo-LC-Biotin (Pierce, Rockford, IL) in a concentration to reach a biotin:CyaA molar ratio of \~20:1. Biotin coupling was performed at 25°C and was stopped after 40 min by washing of the resin with 50 mM Tris-HCl, pH 8.0 solution, and then extensively with PBS. Purified biotinylated CyaA (CyaA-biotin) was then eluted with 50 mM HEPES, 8 M urea and 2 mM EDTA. To label CyaA and its mutant variants with Dyomics 647 (Dy647), the Phenyl-Sepharose column was washed with 50 mM sodium bicarbonate (pH 8.3) and the beads were subsequently resuspended in the same buffer containing Dy647-NHS ester (Dyomics, Jena, Germany) in a concentration to reach a Dy647:protein molar ratio of \~6:1. Labeling was performed at 25°C for 2 hr, the column was washed with 50 mM Tris-HCl (pH 8.0) and labeled proteins were eluted in a buffer containing 50 mM Tris-HCl (pH 8) and 8 M urea. The binding, cell-invasive and hemolytic activities of labeled CyaA-derived proteins were determined as described elsewhere ([@bib54]) and were comparable (\>90%) to activities of untreated CyaA.

Establishment of stably transfected cell lines {#s4-6}
----------------------------------------------

A CHO cell line stably expressing the CD18 subunit (CHO-CD18) was established and used for cell surface expression of the CD11 subunits or their respective chimeric/mutant variants. Briefly, 0.8 μg of a highly purified plasmid DNA containing the appropriate integrin cDNA insert was mixed with 2 μl of Lipofectamine 2000 (Invitrogen, Grand Island, NY) in 100 μl of Opti-MEM I medium (Invitrogen, Grand Island, NY) and the mixture was incubated at 25°C for 20 min. The DNA:lipofectamine mix was added to CHO cells (\> 90% confluency) in F12K medium with 10% FCS. After 6 hr at 37°C, the medium was changed, the transfected cells were cultured for 24 hr and then transferred to F12K medium supplemented with 10% FCS, ATB and 1000 μg/ml of G418 (InvivoGen, San Diego, CA) and/or 600 μg/ml of zeocin (InvivoGen, San Diego, CA) to select stable transfectants for 10 days.

Stably transfected CHO cells were stained with anti-CD11a, anti-CD11b, anti-CD11c and/or anti-CD18 mAbs labeled with AF488, FITC, or APC and cells expressing high levels of integrin molecules were selected, using a FACS Vantage cell sorter (Becton Dickinson, Franklin Lakes, NJ), by sorting single cells into individual wells of 96-well plates containing F12K medium supplemented with 10% FCS, ATB and 600 μg/ml of G418 and/or 300 μg/ml of zeocin. After 3 weeks, the cells from positive wells were expanded, stained with mAbs recognizing the integrin subunits and CHO clones expressing similar amounts of integrin molecules on the cell surface (the maximum difference between surface expression of mutant integrins and intact CR3 was ± 30%) were identified by flow cytometry on a FACS LSR II instrument (BD Biosciences, San Jose, CA). To monitor that the levels of integrin expression on the cell surface of CHO transfectants remained constant, the amounts of surface-expressed integrin molecules were systematically quantified in each experiment by staining with mAbs and subsequent flow cytometry analysis. The obtained mean fluorescence intensity (MFI) values from integrin detection were used to normalize the relative values of CyaA binding to cells.

To produce the secreted form of the integrin ectodomain (sCR3), CHO cells were co-transfected with plasmids harboring cDNAs encoding sCD11b and sCD18. A stably transfected cell line was established and individual cells were cloned from the bulk cell population using a FACS Vantage cell sorter. Stably transfected CHO-sCR3 cells were screened for secretion of the integrin ectodomain by a sandwich ELISA, using the MEM-48 mAb recognizing the CD18 subunit as a capture antibody and the biotinylated MEM-174 mAb directed against the CD11b subunit as detection antibody, respectively. The CHO-sCR3 clone with the highest secretion level of sCR3 was selected for further work.

Production, purification and visualization of the CR3 ectodomain {#s4-7}
----------------------------------------------------------------

CHO-sCR3 cells were cultured in F12 medium supplemented with 10% FCS at 37°C and culture supernatants were harvested every week. sCR3 was purified from the filtered culture supernatant by using an immunoaffinity chromatography matrix prepared by a covalent linkage of MEM-174 mAb to Cyanogen bromide (CNBr)-activated Sepharose 4B beads (GE Healthcare, Piscataway, NJ). The bent and extended conformers of the sCR3 ectodomain were separated by gel filtration chromatography on Superdex 200 HR (GE Healthcare, Piscataway, NJ) in HBSS buffer complemented with 2 mM CaCl~2~ and 2 mM MgCl~2~. The freshly separated conformers of sCR3 were directly applied on glow-discharged carbon copper grids ([@bib5]), stained with 0.75% uranyl formate, and visualized in a Philips CM 100 transmission electron microscope (FEI, Eidhoven, Netherlands) equipped with a MegaViewII slow scan camera controlled by AnalySis 3.2 software (Olympus Soft Imaging Solutions, Münster, Germany).

CyaA and mAbs binding to cells expressing integrin molecules {#s4-8}
------------------------------------------------------------

All assays were performed in HEPES-buffered salt solution (HBSS buffer; 10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM KCl) complemented with 2 mM CaCl~2~, 2 mM MgCl~2~, 1% (w/v) glucose and 1% (v/v) FCS (cHBSS) in 96-well culture plates (Nunc, Roskilde, Denmark). For staining of integrin molecules on cell surface by mAbs, 2x10^5^ transfected CHO cells were incubated for 30 min at 4°C in 50 µl of cHBSS buffer containing mAbs diluted according to manufacturer´s instructions. For CyaA binding assay, 2x10^5^ transfected CHO cells were incubated in 100 µl of cHBSS buffer containing 2 µg/ml of CyaA-biotin (the concentration giving approximately a half-maximal binding of the toxin to CHO cells expressing intact CR3) for 30 min at 4°C. The surface-bound CyaA-biotin was stained with streptavidin-PE (diluted 1:400; eBioscience, San Diego, CA) for 30 min at 4°C. After washing, cells were resuspended in HBSS and analyzed by flow cytometry in the presence of 1 µg/ml of propidium iodide, or Hoechst 33258. Data were analyzed using the FlowJo software (Tree Star, Ashland, OR) and appropriate gatings were used to exclude cell aggregates and dead cells. CyaA binding was expressed as percentage of toxin binding to CHO cells expressing the native form of CR3: ((MFI of cells expressing the mutant integrin - MFI of mock transfected CHO cells) / (MFI of cells expressing intact CR3 - MFI of mock transfected CHO cells)) x 100.

Blocking of CyaA binding by mAbs {#s4-9}
--------------------------------

For blocking of CyaA binding to CR3 by mAbs, 2x10^5^ CHO-CD11b/CD18 cells were preincubated for 15 min at 4°C in the presence of saturating concentrations of different mAbs in 45 µl of cHBSS buffer. CHO-CD11b/CD18 cells incubated with isotype control mAbs or with cHBSS buffer alone were used as controls. 5 µl of CyaA-biotin was then added to the cells in the continuous presence of the mAbs to a final concentration of 2 µg/ml and incubation was continued for 30 min at 4°C. CyaA binding was determined by flow cytometry as described above and expressed as percentage of toxin binding to CHO-CD11b/CD18 cells treated without mAb: ((MFI of mAb-treated cells incubated with CyaA - MFI of mAb-untreated cells incubated without CyaA) / (MFI of mAb-untreated cells incubated with CyaA - MFI of mAb-untreated cells incubated without CyaA)) x 100.

cAMP assay {#s4-10}
----------

1x10^5^ CHO transfected cells were incubated with various concentrations of CyaA ranging from 0 to 20 ng/ml for 30 min at 37°C in D-MEM and the reaction was stopped by addition of 0.2% Tween-20 in 50 mM HCl. Samples were boiled for 15 min at 100°C, neutralized by addition of 150 mM unbuffered imidazole and cAMP levels were determined as described previously ([@bib38]). Due to the extremely high specific catalytic activity of the AC domain, the concentration of CyaA in the cAMP assay was two to three orders of magnitude lower than the toxin amount used in the CyaA binding assay.

Binding of CyaA to the bent and extended conformation of CR3 {#s4-11}
------------------------------------------------------------

A leukocyte-enriched fraction was prepared from fresh human blood of healthy donors by hypotonic lysis of red blood cells. Briefly, 1 ml of whole blood was diluted to 25 ml of ice-cold 0.2% NaCl solution, incubated for 30 s, and isotonicity of the solution was restored by addition of 25 ml of ice-cold 1.6% NaCl. The suspension was centrifuged for 6 min at 250 g and the pelleted leukocytes were resuspended in 0.5 ml of the pre-warmed DMEM medium. The cells were treated without or with 100 nM phorbol 12-myristate 13-acetate (PMA) or 1 mM Mn^2+^ ions for 15 min at 37°C to activate CR3. 100 µl aliquots containing 2x10^5^ cells were immediately stained with OKM-1 mAb recognizing both CR3 conformations, or with MEM-148 mAb recognizing only the extended integrin conformation, or with different concentrations of Dy647-labeled CyaA, in a combination with anti-CD14 mAb. After 2 min, cells were analyzed by flow cytometry in the presence of 1 µg/ml of Hoechst 33258. Data were analyzed using the FlowJo software (Tree Star, Ashland, OR) and live monocytes, gated based on light-scatter characteristics and CD14-positivity (monocytes did not change the level of surface expression of CR3 after incubation with PMA/Mn^2+^ and/or CyaA), were used for assessment of CyaA binding.

Isolation and purification of intact LFA-1 {#s4-12}
------------------------------------------

Human peripheral blood mononuclear cells were isolated from leukopacks of healthy donors using the Ficoll-Paque Plus density gradient centrifugation and were lysed with 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X 100, containing a protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). LFA-1 was purified from cell lysates using the anti-CD11a mAb MEM-25 coupled to CNBr-activated Sepharose 4B beads (GE Healthcare, Piscataway, NJ).

Surface plasmon resonance (SPR) {#s4-13}
-------------------------------

SPR measurements were performed at 25°C using a ProteOn XPR36 protein interaction array system (Bio-Rad Laboratories, Hercules, CA). The freshly separated bent and extended conformers of the sCR3 ectodomain and the freshly purified LFA-1 integrin were diluted to concentrations of 1--20 µg/ml in 10 mM acetate buffer (pH 5.0) and immobilized on a GLC chip using a ProteOn amine coupling kit (Bio-Rad Laboratories) at a flow rate of 30 µl/min. Non-reacted activated groups were blocked by the injection of 1 M ethanolamine (pH 8.5). The subsequent SPR measurements were carried out in 10 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl~2~ and 0.005% Tween 20 at a flow rate of 100 µl/min for both the association and the dissociation phase of the sensograms. To minimize non-specific binding and mass transfer effects, three coupling concentrations of each sCR3 conformer (leading to refractive index changes of 400, 800 and 1200 RU) were tested. Initial experiments at each of the sCR3 coating concentrations were conducted with CyaA∆H at concentrations ranging from 20 to 320 µg/ml. The initial estimates of k~off~ values then showed a concentration independence at all coupling levels, indicating that artifacts from analyte rebinding and mass transfer effects could be ruled out. Consequently, a coupling level of 1200 RU and flow rate of 100 µl/ml was chosen for all remaining experiments.

The CyaA∆H protein was serially diluted in running buffer to concentrations of 20, 40, 80, 160 and 320 µg/ml and injected in parallel ('one-shot kinetics') over the immobilized sCR3 and LFA-1 surface. Response curves were evaluated using the ProteOn Manager software (Bio-Rad Laboratories). The sensograms were corrected for sensor background by interspot referencing (the sites within the 6×6 array, which are not exposed to ligand immobilization but are exposed to analyte flow), and double referenced by subtraction of analyte (channel 1--5) using a ´'blank´' injection (channel 6). The data were analyzed by global fitting of the response curves using a 1:1 Langmuir binding kinetics and a bivalent analyte model to determine the kinetic association and dissociation rate constants. The Langmuir-type model assumes the interaction between ligand (L) and analyte (A) resulting in a direct formation of the final complex (LA): $\operatorname{}\text{L} + \text{A}\overset{{ka},{kd}}{\leftrightarrow}\text{LA}$, where k~a~ and k~d~ are the association and the dissociation rate constants, respectively. The bivalent analyte model assumes two-step association process: $\operatorname{}\text{L} + \text{A}\overset{{ka}1,{kd}1}{\leftrightarrow}\text{LA} + \text{L}\overset{{ka}2,{kd}2}{\leftrightarrow}\text{LLA}$, where the first binding event is described by k~a1~ and k~d1~, while k~a2~ and k~d2~ describe the association and dissociation of the second binding event, respectively. Fitting of the binding curves revealed that the bivalent analyte model described the interaction of CyaA∆H with immobilized sCR3 significantly better in terms of reduced χ^2^ value and residual statistics than the simple 1:1 Langmuir binding model.

Differential equations of the bivalent analyte model {#s4-14}
----------------------------------------------------

 *d*\[L\]/*dt* = −(2 × k~a1~ × \[L\] × \[A\] -- k~d1~ × \[LA\]) -- (k~a2~ × \[LA\] × \[L\] -- 2 × k~d2~ × \[LLA\])

*d*\[LA\]/*dt* = (2 × k~a1~ × \[L\] × \[A\] -- k~d1~ × \[LA\]) -- (k~a2~ × \[LA\] × \[L\] -- 2 × k~d2~ × \[LLA\])

*d*\[LLA\]/*dt* = (k~a2~ × \[LA\] × \[L\] -- 2 × k~d2~ × \[LLA\])

  Parameter   Description                                                Fitting status
  ----------- ---------------------------------------------------------- ----------------
  L           Concentration of free ligand (RU)                          Constant
  A           Concentration of free analyte (M)                          Constant
  LA          Concentration of ligand-analyte complex (RU)               Constant
  LAA         Concentration of two ligand-analyte complex (RU)           Fit globally
  k~a1~       Association rate constant for A + 2L ⇌ LA (M^-1^s^-1^)     Fit globally
  k~d1~       Dissociation rate constant for LA⇌ 2L + A (s^-1^)          Fit globally
  k~a2~       Association rate constant for LA + L ⇌ LLA (RU^-1^s^-1^)   Fit globally
  k~d2~       Dissociation rate constant for LLA ⇌ LA + L (s^-1^)        Fit globally

Fitting formulas of the bivalent analyte model {#s4-15}
----------------------------------------------

### JacobN association {#s4-15-1}

B = (Rmax-yJacob\[0\]-2\*yJacob\[1\]);

dfdy\[0\]\[0\] = -2\*Ka1\*Conc - Kd1 - Ka2\*(B - yJacob\[0\]);

dfdy\[0\]\[1\] = 2\*(-2\*Ka1\*Conc + Ka2\*yJacob\[0\] + Kd2);

dfdy\[1\]\[0\] = Ka2\*(B - yJacob\[0\]);

dfdy\[1\]\[1\] = -2\*(Ka2\*yJacob\[0\] + Kd2);

### JacobN dissociation {#s4-15-2}

B = (Rmax-yJacob\[0\]-2\*yJacob\[1\]);

dfdy\[0\]\[0\] = - Kd1 - Ka2\*(B - yJacob\[0\]);

dfdy\[0\]\[1\] = 2\*(Ka2\*yJacob\[0\] + Kd2);

dfdy\[1\]\[0\] = Ka2\*(B - yJacob\[0\]);

dfdy\[1\]\[1\] = -2\*(Ka2\*yJacob\[0\] + Kd2);

### Derive association {#s4-15-3}

B = (Rmax-yDerive\[0\]-2\*yDerive\[1\]);

dydt\[0\] = B\*(2\*Ka1\*Conc - Ka2\*yDerive\[0\]) - Kd1\*yDerive\[0\] + 2\*Kd2\*yDerive\[1\];

dydt\[1\] = Ka2\*B\*yDerive\[0\] - 2\*Kd2\*yDerive\[1\];

### Derive dissociation {#s4-15-4}

B = (Rmax-yDerive\[0\]-2\*yDerive\[1\]);

dydt\[0\] = B\*(- Ka2\*yDerive\[0\]) - Kd1\*yDerive\[0\] + 2\*Kd2\*yDerive\[1\];

dydt\[1\] = Ka2\*B\*yDerive\[0\] - 2\*Kd2\*yDerive\[1\];

Syk activation, immunoprecipitation and Western blotting {#s4-16}
--------------------------------------------------------

Experiments were performed on the human monocytic cell line, THP-1, and primary human monocytes isolated from leukopacks using the Ficoll-Paque Plus density gradient centrifugation followed by a magnetic cell-sorting using anti-CD14 magnetic beads to collect the CD14 positive fraction with an AutoMACS Pro Separator (Miltenyi Biotec, Bergisch Gladbach, Germany).

To opsonize zymosan with iC3b, the complement activation cascade in serum was used. Zymosan A (Sigma-Aldrich, St. Louis, MO) was incubated in 50% human serum at 37°C for 30 min. Zymosan particles were washed with PBS to remove unattached components of serum and dissolved in DMEM without FCS before use for treatment of cells. Unopsonized zymosan was prepared by incubating zymosan particles in PBS at 37°C for 30 min.

CyaA or genetically detoxified CyaA (CyaA-AC^-^) was diluted to final concentrations from concentrated stocks in DMEM without FCS. For the time course experiments, 3x10^6^ THP-1 cells were treated with 30 ng/ml of toxin for different time points at 37°C. For concentration dependence experiments, 3x10^6^ THP-1 cells were incubated at 37°C with different amounts of CyaA or CyaA-AC^-^ for 15 or 30 min, respectively. 3x10^6^ THP-1 cells treated with 300 µg of opsonized or unopsonized zymosan were used as positive and negative controls, respectively. THP-1 cells treated with TUC buffer (50 mM Tris-HCl (pH 8.0), 8 M urea, 2 mM CaCl~2~) diluted to the same level as the highest toxin concentration were used as an additional control.

To investigate the effect of elevated cAMP levels on Syk activation, 3x10^6^ THP-1 cells or primary monocytes were pretreated with 300 ng/ml of CyaA, CyaA-AC^-^, or TUC buffer for 15 min, followed by treatment with iC3b-opsonized zymosan for 30 min at 37°C. Cells treated with TUC buffer followed by unopsonized zymosan were used as a control.

To examine the effect of cAMP on already activated Syk, 3x10^6^ THP-1 cells or primary monocytes were incubated for 15 min with iC3b-opsonized zymosan followed by addition of 300 ng/ml of CyaA, CyaA-AC^-^, or TUC buffer for 30 min at 37°C. Cells incubated with unopsonized zymosan followed by TUC buffer were used as a control.

The reactions were carried out in DMEM with 10% FCS and no antibiotics. Triton X lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM Na~3~VO~4~, 10 mM NaF, 0.13% SDS, 1% Triton X 100 and EDTA-free protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany)) was used to stop the reaction and to lyse the cells at the respective time points. Cell lysates were collected and debris was removed by centrifugation. Aliquots of lysates were taken to detect the total amounts of Syk in individual samples. Tyrosine phosphorylated proteins were immunoprecipitated using anti-phosphotyrosine mAb (P-Tyr-01) for 3 hr at 4°C and bound to protein A-coupled sepharose beads (GE Healthcare, Uppsala, Sweden) overnight at 4°C. The beads were washed in Triton X lysis buffer and boiled with Laemmli loading buffer. The proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Pall Corporation, Pensacola, FL). The membrane was blocked with 5% BSA in TBS-T (25 mM Tris-HCl (pH 7.4), 300 mM NaCl, 2.6 mM KCl, 0.3% Tween 20) for 60 min at 25°C and incubated with anti-Syk mAb (SYK-01) for 1 h at 25°C. Upon washing with TBS-T, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse IgG antibody for 1 hr and washed with TBS-T. The blots were developed using SuperSignal West Femto maximum sensitivity substrate (Thermo Scientific, Rockford, IL) and the chemiluminescent signal was recorded using an ImageQuant LAS 4000 Imager (GE Healthcare, Uppsala, Sweden).

3D structure modeling of a CyaA-CR3 interaction {#s4-17}
-----------------------------------------------

The 3D structure model of the CR3 complex was generated with the Modeler suite of programs ([@bib20]) using the known 3D structure of the highly homologous CR4 complex (PDB ID 3K72, chains A B; omitting the highly flexible I-domain and the C-terminal domains that are not deposited in the PDB file) ([@bib82]). The structure of CR3 was then equilibrated to allow partial spatial rearrangement of the protein. Short (2 ns) MD simulation was performed using OpenMM ([@bib17]) Zephyr ([@bib25]) (code freely available on <https://simtk.org/home/zephyr>) implementing GPU accelerated version of GROMACS suite of programs ([@bib71]). Implicit solvation (GBSA, ε=78.3, "'accurate water"' with collision interval of 10.99 fs) in combination with parm96 force-field was used ([@bib41]). The initial structure was next optimized and refined by simulation at 300 K with time step of 2 fs.

The structure of the amino acid segment 1166--1287 of CyaA, which was found to be responsible for CD11b binding ([@bib19]), was predicted using I-TASSER ([@bib60]).

To analyze the binding mode of CyaA to CR3, a flexible side chain docking of the modeled region 1166--1287 of CyaA to the CR3 complex was performed using the ClusPro server ([@bib12]).

The 3D structure of the full-length CD11b subunit was subsequently modeled using the structure prediction server I-TASSER ([@bib60]). The resulting structure and orientation of the I-domain and of the C-terminal segment agreed with the crystal structure of CR4 ([@bib82]).

Statistical analysis {#s4-18}
--------------------

Results were expressed as the arithmetic mean ± standard deviation (SD) of the mean. Student's t-test was used to calculate statistical significance when two groups were compared. To test more than two groups, statistical analysis was performed by one-way ANOVA followed by Dunnett\'s post-test, comparing all the samples with the control. GraphPad Prism 6.0 (GraphPad Software) was used to perform statistical analysis. Significant differences are indicated by asterisks (\*, p\<0.05; \*\*, p\<0.01; \*\*\*, p\<0.001; \*\*\*\*, p\<0.0001).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"*Bordetella* adenylate cyclase toxin is a unique ligand of the integrin complement receptor 3\" for peer review at *eLife*. Your submission has been favorably evaluated by Richard Losick (Senior editor), a Reviewing editor, and three reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission. As you will see the major concerns are related to the methodology used to distinguish between active and inactive integrin conformations. The summaries of your work written by the three reviewers as well as the detailed concerns that need to be addressed are detailed below.

Essential revisions:

1\) [Figure 1](#fig1){ref-type="fig"} and experiments related to it.

The authors have overexpressed in CHO cells both α~M~ (CD11b) and α~X~ (CD11c) integrins and shown that CyaA only binds to α~M~. After that they have overexpressed numerous α~M~/α~X~ swaps.

The conclusion that CyaA cannot bind to α~M~ I-domain is based on the construct in which αI-domain region has been deleted.

The weakest CyaA binder was a receptor in which α~M~ contained α~X~ residues 614-682. These residues are said to locate \"next to the β-propeller domain\", but they are actually part of the \"thigh\" domain (In [Figure 4A](#fig4){ref-type="fig"} they have been correctly marked there). The structure and function of this domain should be discussed in more detailed manner.

The unconventional binding mechanism of CyaA is not a completely novel observation since Guermonprez et al. 2001 have reported that Mg^2+^ is not needed for CyaA recognition by α~M~β~2~ integrin. This fact should be discussed.

2\) [Figure 2](#fig2){ref-type="fig"}.

The data based on antibodies support the existence of many binding site. Even the αI domain antibodies have a statistically significant effect. Can these antibodies activate/inactivate integrin conformation?

3\) [Figure 4](#fig4){ref-type="fig"}.

The authors have used molecular modelling to indicate that it is structurally possible that CyaA binds to the thigh domain and propose that this takes place via electrostatic interactions. Based on the model they have done arginine to alanine mutations and indicate that simultaneous mutation of three arginine residues affects CyaA binding. Despite the fact that this observation suggests an interaction between CyaA and thigh domain (in addition to binding the β-propeller) more direct evidence is needed no really name the thigh domain as CyaA binding site. Could it be possible to produce α~M~ and α~X~ thigh domains as recombinant proteins?

4\) [Figure 5](#fig5){ref-type="fig"}.

To test, whether CyaA binds to the bent or to the extended integrin conformation the authors have treated cells with an integrin activator PMA. PMA increases the number of activated integrins on cell surface and decreases CyaA binding. The observation is interesting, but one should remember that PMA has also many other effects on cells in general and, more specifically, on integrins. It may, for example, increase integrin clustering and mask binding sites in integrin legs. A better experiment would have been to use mutant integrins (e.g. E320A in α~M~) that favour the bent conformation together with integrins harbouring a gain-of-function mutation. Mn^2+^ could also have been used to activate integrins.

The authors have also isolated soluble α~M~β~2~ integrins and then managed to separate bent and extended conformations and to attach them to Biacore chips. It is quite surprising that the highly dynamic integrins can keep their conformations, but at least the data based on the conformation specific antibodies ([Figure 5C, D](#fig5){ref-type="fig"}) supports this idea. However, the Biocore curves seem to be more or less identical ([Figure 5E and F](#fig5){ref-type="fig"}) and indicate at best only marginal difference between the bent and the extended conformation. [Table 1](#tbl1){ref-type="table"} shows the calculations based on bivalent analyte model. The authors should indicate a scientific reason why this model was chosen. They should also show the K~d~ values in addition to association and dissociation rates. How many times this experiment was repeated? Was the difference statistically significant, when independent experiments were combined?

The idea that the α~M~β~1~ integrin is in bent conformation is in conflict with a previously published report (Guermonprez et al. 2001), which indicates that Ca^2+^ is needed for the interaction and that EDTA and EGTA inhibit it. Depletion of Ca^2+^ forces the integrins to bent conformation (and should increase CyaA binding if it takes place to the non-activated integrin). The authors should be able to solve this critical discrepancy.

Interestingly, CyaA has been reported to bind α~L~β~2~ integrin that is in the activated conformation (Paccani et al. 2011). Is there a fundamental difference in the action of α~M~ when compared α~L~? Can this be explained by structural comparisons? Can α~L~ thigh domain bind to CyaA? Can α~M~/α~L~ I domains bind to CyaA?

The experiment in [Figure 9](#fig9){ref-type="fig"} is suggesting that α~L~β~2~ could not recognize CyaA. Since this is in conflict with a previously paper, the authors should control the experiment very carefully and e.g. show that α~L~β~2~ is functional as YFP fusion protein. Does native α~L~ support CyaA entry in these assays?

5\) [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} (Conclusion [Figure 8](#fig8){ref-type="fig"}).

The data nicely indicates that CyaA can inhibit iC3b induced phosphorylation of SYK. Based on the conclusion figure, one would also expect experiments testing whether CyaA prevents/allows α~M~β~2~ binding to iC3b? Similarly CyaA should not be able to affect recombinant α~M~ I-domain binding to iC3b.

6\) Activation of the integrin with PMA decreases the capacity of CyaA to associate with these integrins. It would be interesting to know whether this is translated into a lower induction of cAMP by CyaA in target cells.

7\) A weakness of that manuscript is the absence of numerical values for the respective K~d~ in the text. There are equations given in Materials and methods, a table, but these numerical values should be introduced in the text, for the deleted mutants, substituted mutants and various target forms developed in the manuscript.

Reviewer summaries:

Reviewer\#1:

The adenylate cyclase toxin (CyaA) is a virulence factor of *Bordetella pertussis*. CyaA has been reported to bind to two integrin-type receptors on cell surface, namely α~M~β~2~ and α~L~β~2~, while a third integrin in the same subfamily, α~X~β~2~, cannot recognize CyaA. In this manuscript the authors show evidence that CyaA binds to the non-activated (bent) α~M~β~2~ state instead of the activated (extended) conformation. Moreover, they suggest that CyaA binding site is not in the αI (αA) domain. The exact significance of CyaA binding to cellular receptors is not clear (Its internalization is supposed to take place directly through plasma membrane, not via endocytosis, see Landant and Ullmann, 1999), but the observations are still interesting for integrin biology, since very little is known about the putative atypical ligand binding sites and mechanisms. Still, ligand binding to the bent integrin conformation is not entirely new idea, since non-activated integrins may participate e.g. in leukocyte rolling and human echovirus-1 binds to the non-activated α~2~β~1~ integrin.

The finding that CyaA binds to beta-propeller/thigh-domain in α~M~β~2~ and favour the bent integrin conformation would be important. However, based on the experiments shown in this manuscript, these conclusions are not fully justified. In some important points there are unsolved discrepancies when compared to previously published reports. In general the authors should study previous literature more carefully and in the discussion they should stress the structural aspects instead of signaling.

Reviewer\#2:

The work presented by Osicka et al., describes the mode of interaction of the adenylate cyclase toxin CyaA from *Bordetella pertussis* with the integrin complement receptor 3 CR3 (CD11b/CD18) and how this modulates the activation of Syk-kinase downstream of the CR3.

By conducting two different approaches (CD11 b/c chimera and antibody interference) the authors first define that CyaA binds to the region 614-682 outside the I-domain. They also show that the swapping this stretch of amino acids between CD11b and CD11c confers to CD11c the capacity of binding to CyaA. The 3D structure modeling-coupled to mutagenesis followed by functional analysis allow the authors to identify in CyaA a group of negatively charged amino-acids implicated in this interaction and a group of positively charged amino-acids in their vicinity in CD11b. This convincingly points for the importance of electrostatic interactions in the interaction of the toxin with its receptor. They also established that CyaA binds preferentially to the close conformation / inactive form of the integrin. They also show that CyaA has a blocking effect on the activation of Syk prior to and after addition of iC3b-zymosan, in a AC independent and dependent manner, respectively.

This elegant work is well presented and the conclusions are thoroughly established by complementary approaches.

This work characterizes a new mode of interaction of a bacterial toxin with its integrin receptor that is critical to block Syk-dependent innate immune responses.

Reviewer \#3:

Osicka and coworkers here reveal the major domains involved in the interactions between the Bordetella pertussis adenylate cyclase Cya and its major receptor CR3. Moreover, they dissected the signaling of a kinase Syk that is important in the CR3 signaling cascade to demonstrate that, after Cya integration into the cytoplasma, the elevation of cyclic AMP is responsible for the blockade of Syk phosphorylation. Overall, this is a huge work with many techniques, thoroughly conducted and abundantly explained and illustrated. There remains some weaknesses that should be easily correctly in order to render the text more substantial.

10.7554/eLife.10766.034

Author response

Essential revisions:

1\) [Figure 1](#fig1){ref-type="fig"} and experiments related to it.

*The authors have overexpressed in CHO cells both* α*~M~ (CD11b) and* α*~X~ (CD11c) integrins and shown that CyaA only binds to α~M~. After that they have overexpressed numerous α~M~/α~X~ swaps.*

The conclusion that CyaA cannot bind to α~M~ I-domain is based on the construct in which αI-domain region has been deleted. The weakest CyaA binder was a receptor in which α~M~ contained α~X~ residues 614-682. These residues are said to locate \"next to the beta-propeller domain\", but they are actually part of the \"thigh\" domain (In [Figure 4A](#fig4){ref-type="fig"} they have been correctly marked there). The structure and function of this domain should be discussed in more detailed manner.

We thank the reviewers for this point. The segment located between residues 614-682 encompasses, indeed, the C-terminal end of the last repeat of the β-propeller domain and the N-terminal portion of the thigh domain of CD11b. This is now appropriately described in the revised manuscript and the structural and functional features of the β-propeller/thigh region are described in more detailed manner in the Discussion section.

The unconventional binding mechanism of CyaA is not a completely novel observation since Guermonprez et al. 2001 have reported that Mg^2+^ is not needed for CyaA recognition by α~M~β~2~ integrin. This fact should be discussed.

As suggested, it is now mentioned in the revised manuscript that Guermonprez et al. 2001 observed Mg^2+^-independent CyaA binding to CR3 and suggested that CyaA might be an I-domain-independent ligand of the integrin.

2\) [Figure 2](#fig2){ref-type="fig"}.

The data based on antibodies support the existence of many binding site. Even the αI domain antibodies have a statistically significant effect. Can these antibodies activate/inactivate integrin conformation?

To address the question of the reviewers, whether the I-domain-specific antibodies can activate/inactivate integrin conformation, the CHO cells expressing intact CR3 were pre-incubated with the 44 and 2LPM19c mAbs and the conformation of the integrin was probed with the MEM-148 mAb. As now shown in the newly added [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, neither binding of these two mAbs, nor binding of any other mAb used in [Figure 2](#fig2){ref-type="fig"} did cause any activation of the integrin. As clearly shown in [Figure 1](#fig1){ref-type="fig"}, the I-domain is not involved in the multivalent interaction of CyaA with CR3. Therefore, we conclude that the statistically significant decrease of CyaA binding to CR3, in the presence of the I-domain-specific mAbs 44 and 2LPM19c ([Figure 2](#fig2){ref-type="fig"}), resulted from steric hindrance of the 150 kDa-large I-domain-bound mAbs and not from activation of the integrin.

3\) [Figure 4](#fig4){ref-type="fig"}.

The authors have used molecular modelling to indicate that it is structurally possible that CyaA binds to the thigh domain and propose that this takes place via electrostatic interactions. Based on the model they have done arginine to alanine mutations and indicate that simultaneous mutation of three arginine residues affects CyaA binding. Despite the fact that this observation suggest an interaction between CyaA and thigh domain (in addition to binding the β-propeller) more direct evidence is needed no really name the thigh domain as CyaA binding site. Could it be possible to produce α~M~ and α~X~ thigh domains as recombinant proteins?

We agree with the reviewers that demonstration of direct CyaA binding to the isolated segment 614-682 of CD11b (or the entire thigh domain) would potentially bring an added value. However, due to the complex and multivalent nature of CyaA interaction with CR3, such experiments are not likely to yield conclusive results. In contrast to binding of some endogenous ligands to the isolated recombinant I-domain of CR3 (Zhou et al., JBC, 1994), CyaA appears to recognize in a first step the presence of N-linked glycan chains of the C-terminal part of CD11b (Hasan et al. 2015), which is a critical prerequisite for toxin binding to CR3 (Morova et al. 2008). However, no N-glycan chains necessary for CyaA binding appear to be present within the segment 614-682 (Hasan et al. 2015). Moreover, as discussed in the manuscript and above, recognition of several segments of CD11b appears to contribute to the full capacity of CR3 to bind CyaA. Engagement of these segments likely facilitates or stabilizes the higher-affinity interaction of CyaA with the principal binding site located within the segment 614 to 682. Further, as now documented in the newly added [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, CyaA recognizes the CD11b subunit only when this is in the heterodimeric complex with CD18. This strongly suggests that proper folding of the CD11b segment on the scaffold of the CD18 subunit is essential for toxin binding. This may explain why we failed to observe any significant inhibition of CyaA binding to the CD11b/CD18 heterodimer in the presence of a synthetic peptide derived from the 614-682 segment of CD11b (data not shown). Therefore, we opted here for a \'transplantation\' experiment yielding positive evidence, where the 614-682 segment of CD11b was swapped into the context of the CD11c subunit of CR4 and conferred on CR4 a substantial capacity to bind CyaA and support toxin penetration into cells ([Figure 3](#fig3){ref-type="fig"}). We consider this as providing convincing evidence that the segment 614-682 is the principal binding site of CyaA. This conclusion is then strongly supported by loss of CyaA binding (i) upon swapping of the corresponding segment 614-682 of CD11c into CD11b ([Figure 1](#fig1){ref-type="fig"}); (ii) in the presence of mAbs competing with the toxin for the same segment ([Figure 2](#fig2){ref-type="fig"}), and (iii) upon site-directed mutagenesis of the segment 614-682 ([Figure 4](#fig4){ref-type="fig"}), respectively.

4\) [Figure 5](#fig5){ref-type="fig"}.

To test, whether CyaA binds to the bent or to the extended integrin conformation the authors have treated cells with an integrin activator PMA. PMA increases the number of activated integrins on cell surface and decreases CyaA binding. The observation is interesting, but one should remember that PMA has also many other effects on cells in general and, more specifically, on integrins. It may, for example, increase integrin clustering and mask binding sites in integrin legs. A better experiment would have been to use mutant integrins (e.g. E320A in α~M~) that favour the bent conformation together with integrins harbouring a gain-of-function mutation. Mn^2+^ could also have been used to activate integrins.

As suggested by the reviewers, Mn^2+^ ions were used to activate CR3 on the surface of primary human monocytes. Similarly as with PMA, CyaA binding and cAMP intoxication of cells with the activated integrin was reduced in comparison with cells that were not treated with Mn^2+^ ions. The results addressing this issue are now shown in the newly added [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. To control the possibility that activation of CR3 with PMA or Mn^2+^ ions would mask CyaA binding site in integrin legs due to increased integrin clustering, we used the OKM1 mAb that recognizes the same segment 614-682 of CD11b as CyaA. In contrast to reduced binding of CyaA to the activated CR3 integrin, no such reduction of binding was observed with the OKM1 mAb ([Figure 5A](#fig5){ref-type="fig"}and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). The potential PMA-provoked integrin clustering thus does not appear to be involved in the masking of the CyaA binding site in integrin legs.

The authors have also isolated soluble α~M~β~2~ integrins and then managed to separate bent and extended conformations and to attach them to Biacore chips. It is quite surprising that the highly dynamic integrins can keep their conformations, but at least the data based on the conformation specific antibodies ([Figure 5C, D](#fig5){ref-type="fig"}) supports this idea. However, the Biocore curves seem to be more or less identical ([Figure 5E and F](#fig5){ref-type="fig"}) and indicate at best only marginal difference between the bent and the extended conformation. [Table 1](#tbl1){ref-type="table"} shows the calculations based on bivalent analyte model. The authors should indicate a scientific reason why this model was chosen. They should also show the K~d~ values in addition to association and dissociation rates. How many times this experiment was repeated? Was the difference statistically significant, when independent experiments were combined?

The bent and extended conformers of secreted ectodomains of the β~2~ integrins CR4 and LFA-1 could be previously separated on the basis of their distinct hydrodynamic properties by gel permeation chromatography (Nishida et al., Immunity, 2006). Here we applied a similar procedure to isolate the bent and extended conformers of the soluble ectodomain of the β~2~ integrin CR3 (sCR3), documenting the separation by negative stain electron microscopy ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). It is important to note that the sCR3 separation, immobilization on an SPR chip and binding experiments were performed within a single day, in order to limit the extent of possible conformational changes of the purified sCR3 particles. The real time interaction of CyaA∆H with the bent and extended conformations of the sCR3 ectodomain revealed typical binding curves ([Figure 5F, G](#fig5){ref-type="fig"}). These were fitted with several kinetic binding models (e.g. a simple 1:1 Langmuir model, a heterologous ligand model, a conformational change (two-state) model), where only the bivalent analyte model yielded satisfactory results in terms of reduced χ^2^ value and residual statistics that were not sensitive to changes in coupling levels and flow rates. As now stated in the legend to [Table 1](#tbl1){ref-type="table"}, two independent SPR binding experiments were performed in duplicate and the differences between mean values of CyaA∆H binding to the bent and extended conformation of sCR3 were statistically significant (P \< 0.01; Student´s t-test). The determined K~d~ values of the interaction between CyaA∆H and the bent (K~d~ = 2.1x10^-7^ M) or extended (K~d~ = 6.4x10^-7^ M) conformers of sCR3 differed by a factor of \~3 and are now given in the revised text.

The idea that the α~M~β~1~ integrin is in bent conformation is in conflict with a previously published report (Guermonprez et al. 2001), which indicates that Ca^2+^ is needed for the interaction and that EDTA and EGTA inhibit it. Depletion of Ca^2+^ forces the integrins to bent conformation (and should increase CyaA binding if it takes place to the non-activated integrin). The authors should be able to solve this critical discrepancy.

The requirement for Ca^2+^ is not in conflict with preferential binding of CyaA to the bent conformer of the CR3 integrin. The reason is that CyaA is itself a calcium-binding protein and the functional folding of its receptor-binding RTX domain does strictly depend on loading of the \~40 Ca^2+^-binding sites formed by the RTX repeats of CyaA (Rose et al., JBC, 1995). Calcium loading then confers on CyaA a conformational change that enables it to bind and penetrate cells (Hewlett et al., JBC, 1991; Rogel et al., JBC, 1992). In the absence of Ca^2+^ ions, the CyaA cannot recognize the CR3 molecule because its RTX domain is not folded (Guermonprez et al. 2001).

*Interestingly, CyaA has been reported to bind α~L~β~2~ integrin that is in the activated conformation (Paccani et al. 2011). Is there a fundamental difference in the action of α~M~ when compared α~L~? Can this be explained by structural comparisons? Can α~L~ thigh domain bind to CyaA? Can α~M~/α~L~ I domains bind to CyaA? The experiment in [Figure 9](#fig9){ref-type="fig"} is suggesting that α~L~β~2~ could not recognize CyaA. Since this is in conflict with a previously paper, the authors should control the experiment very carefully and e.g. show that α~L~β~2~ is functional as YFP fusion protein. Does native α~L~ support CyaA entry in these assays?*Already Guermonprez et al. 2001 have unambiguously demonstrated that CyaA binds selectively and with high affinity the cells expressing CR3, such as the dendritic cells and macrophages, whereas B and T cells, which express only the LFA-1 complex, are recognized by CyaA with very low efficacy, like other cells lacking CR3 and β~2~integrins, such as erythrocytes. Guermonprez et al. summarized their observations as follows: "The lack of efficient binding to CD11c/CD18 transfectants, or CD11a/CD18 expressing cells such as EL4 or LB27.4, also suggests that CD11b/CD18 is the only integrin of the β~2~ family involved in the binding of CyaA to the target cells". We have fully reproduced here the findings of Guermonprez et al. 2001, showing that cells expressing LFA-1 bound about two orders of magnitude less CyaA toxin than cells expressing the same quantities of CR3, when the β~2~integrin expression level per cell was calibrated by using the YFP tag C-terminally fused to either of the alpha integrin subunits ([Figure 9](#fig9){ref-type="fig"}). In addition, there was no statistically significant difference in the levels of CyaA binding to cells expressing high amounts of CD11a-YFP/CD18, of CD11c-YFP/CD18, or not expressing any β~2~ integrin at all ([Figure 9](#fig9){ref-type="fig"}, CyaA binding to cells expressing CD11c-YFP/CD18 was newly added to the figure). This was not surprising, since CyaA has a well-documented capacity to bind and penetrate with a low efficacy the plasma membrane of all cell types lacking CR3 (reviewed in Vojtova et al. 2006; Ladant et al., Trends Microbiol, 1999; Hanski et al., Trends Biochem Sci, 1989).

To make sure that the low (residual) binding of CyaA to LFA-1 was not due to the presence of the YFP tag, we generated a cell line expressing comparable amounts of intact LFA-1 and demonstrated that CyaA binds cells expressing intact LFA-1 as poorly as cells expressing LFA-1 with the YFP tag (added as [Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). In addition, we purified the intact LFA-1 integrin from human peripheral blood mononuclear cells by immunoaffinity chromatography and immobilized it onto an SPR sensor chip. Real-time SPR measurements revealed that CyaA fails to bind the immobilized LFA-1 (added as [Figure 9---figure supplement 3](#fig9s3){ref-type="fig"}). Moreover, cells expressing LFA-1 were intoxicated by CyaA to equally low cAMP levels as the control cells expressing CR4, or lacking any β~2~ integrin. Indeed, cAMP intoxication levels of cells expressing CR3 were over two orders of magnitude higher than those of the control cells (added as [Figure 9](#fig9){ref-type="fig"}, panel B). This is in agreement with previously published data showing that a concentration of 5 ng/ml of CyaA was sufficient to produce 6 pmol of cAMP per 1 million of human THP-1 monocytes expressing CR3 (Ahmad et al., Cell Microbiol, 2015), while \~1600-times higher concentration of CyaA (8 μg/ml) had to be used to yield \~2 pmol of cAMP per 1 million of human blood T-cells or Jurkat T lymphoma cells expressing LFA-1 (Paccani et al. 2011). Moreover, LFA1-expressing Jurkat cells were previously found to bind CyaA as inefficiently as sheep erythrocytes that lack any β~2~ integrin (Gray et al., Infect Immun, 1999). Numerous in vitro studies previously reported that CyaA can penetrate a wide variety of cells lacking any β~2~ integrin, which is simply due to the extremely high specific AC enzyme activity. At \>100 ng/ml concentration, the toxin causes easily detectable increase of intracellular cAMP concentrations over time in essentially any cell type (reviewed in Vojtova et al., Curr Opin Microbiol, 2006; Ladant et al., Trends Microbiol, 1999; Hanski et al., Trends Biochem Sci, 1989).

In conclusion, data obtained in several different laboratories show that CyaA binds and intoxicates cells expressing CR3 with substantially higher efficacy than cells expressing LFA-1. The data further demonstrate that CyaA does not bind LFA-1 any more avidly or in any more specific manner than it interacts through its weak lectin activity with other β~2~ integrin-unrelated glycoproteins or glycolipids of cell surface (Gordon et al., JBC,1989; Vojtova et al., MRT, 2006; Morova et al. 2008).

5\) [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"} (Conclusion [Figure 8](#fig8){ref-type="fig"}).

The data nicely indicates that CyaA can inhibit iC3b induced phosphorylation of SYK. Based on the conclusion figure, one would also expect experiments testing whether CyaA prevents/allows α~M~β~2~ binding to iC3b? Similarly CyaA should not be able to affect recombinant α~M~ I-domain binding to iC3b.

These experiments were, indeed, included as [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"} in the initial manuscript and demonstrated that pre-incubation of monocytes with CyaA causes a partial reduction of iC3b-coated particle binding to CR3-expressing cells. However, a significant decrease of iC3b binding was not observed upon preincubation of monocytes with the CyaA-AC^-^ toxoid that is unable to catalyze conversion of cytosolic ATP to cAMP. Moreover, as revealed by mAbs staining in [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}, pre-incubation with CyaA did not provoke any significant decrease of CR3 levels exposed on cell surface, showing that decreased binding of iC3b-coated particles was not due to CyaA-triggered CR3 internalization. In contrast, pre-incubation of cells with iC3b-opsonized zymosan did not reduce binding of CyaA or CyaA-AC^-^ ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}). It indicates that the CyaA/CyaA-AC^-^ molecules do not directly compete with iC3b for binding to CR3. Instead, the cAMP signaling action of CyaA by an as yet unknown mechanism causes a partial decrease of the iC3b opsonin-binding capacity of CR3 on cell surface.

*6) Activation of the integrin with PMA decreases the capacity of CyaA to associate with these integrins. It would be interesting to know whether this is translated into a lower induction of cAMP by CyaA in target cells.*As suggested by the reviewers, intracellular levels of cAMP produced upon interaction of CyaA with PMA-activated primary monocytes were determined. The results demonstrate that intracellular cAMP levels produced by the toxin are significantly lower in PMA-treated cells than in untreated cells. The data were now added into [Figure 5](#fig5){ref-type="fig"} as the panel C and the corresponding modifications have been made in the main text and in the legend to [Figure 5](#fig5){ref-type="fig"}, respectively.

7\) A weakness of that manuscript is the absence of numerical values for the respective Kd in the text. There are equations given in Materials and methods, a table, but these numerical values should be introduced in the text, for the deleted mutants, substituted mutants and various target forms developed in the manuscript.

With the membrane-penetrating CyaA toxin used in this study, determination of the equilibrium constants (K~d~ values) for binding to the membrane-anchored CR3 receptor variants on cell surface cannot be performed in any meaningful way. This is because the binding of CyaA to the receptor is followed by irreversible insertion of the hydrophobic pore-forming domain and of the acyl chains of the toxin into cellular membrane, which occurs even at low temperature used in the binding assay (Rogel et al., JBC, 1992; El-Azami-El-Idrissiet al. 2003; Masin et al., Biochemistry, 2005). Membrane insertion withdraws the cell-bound toxin molecules from the association-dissociation equilibrium with CR3 and shifts the binding equilibrium to the right, yielding the very high apparent affinities (\~10^-9^ M) reported by Guermonprez et al., JEM, 2001. Therefore, the interaction between CyaA and the various CR3 variants could not be expressed as numerical K~d~ values. Instead, the interaction of CyaA with cells expressing various CR3 mutants was quantified by flow cytometry and expressed as % of binding compared to cells expressing intact CR3.

Since the construction and selection of transfectants and subsequent production and affinity purification of the secreted integrin ectodomain is a rather lengthy and very laborious procedure, this was undertaken here only for the intact CR3. It would go far beyond the scope of the present work to produce and purify the ectodomains of all mutant CR3 variants developed in the manuscript. Therefore, only the K~d~ values of the interaction between CyaA and the bent and extended CR3 ectodomain conformers were determined by SPR. These values were now added into the revised manuscript.

[^1]: *^a^*Two independent SPR binding experiments were performed in duplicate and the differences between mean values of CyaA∆H binding to the bent and extended conformation of sCR3 were statistically significant (p\<0.01; Student's t-test).
